UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~June 30, 2021~~March 31, 2022

☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period fromto

Commission file number: 001-37410

ESSA Pharma Inc.

(Exact name of registrant as specified in its charter)


British Columbia, Canada	~~47-2569713~~98-1250703
(State or other jurisdiction of	(I.R.S. Employer
incorporation or organization)	Identification Number)
Suite 720, 999 West Broadway
Vancouver, BC V5Z 1K5
(Address of principal executive offices, including zip code)
Registrant’s telephone number, including area code: (778) 331-0962
Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Shares	EPIX	Nasdaq Capital Market

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐☒ No ☒☐

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes ☐ No ☒

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☒☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Securities Exchange Act of 1934). Yes ☐ No ☒

The number of outstanding common shares of the registrant, no par value per share, as of ~~August 16, 2021~~May 10, 2022 was ~~43,984,346.~~44,059,700.

Table of Contents

ESSA PHARMA INC.

QUARTERLY REPORT ON FORM 10-Q

For the Quarter Ended ~~June 30, 2021~~March 31, 2022

Table of Contents

	PART I. FINANCIAL INFORMATION	78

Item 1.	Financial Statements and Supplementary Data	78

	Condensed Consolidated Interim Balance Sheets as of ~~June 30, 2021~~March 31, 2022 and September 30, ~~2020~~2021	89

	Condensed Consolidated Interim Statements of Operations and Comprehensive Loss for the three and ~~nine~~six months ended ~~June 30,~~March 31, 2022 and 2021 ~~and 2020~~	910

	Condensed Consolidated Interim Statements of Cash Flows for the ~~nine~~six months ended ~~June 30,~~March 31, 2022 and 2021 ~~and 2020~~	1011

	Condensed Consolidated Interim Statement of Changes in Shareholders’ Equity for the three and ~~nine~~six months ended ~~June 30,~~March 31, 2022 and 2021 ~~and 2020~~	1112

	Notes to Condensed Consolidated Interim Financial Statements	1213

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operation	24

Item 3.	Controls and Procedures	46

	PART II. OTHER INFORMATION	47

Item 1.	Legal Proceedings	47

Item 1A.	Risk Factors	47

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	47

Item 3.	Defaults Upon Senior Securities	47

Item 4.	Mine Safety Disclosures	47

Item 5.	Other Information	47

Item 6.	Exhibits, Financial Statement Schedules	48

	SIGNATURES	49

Table of Contents

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS AND RISK FACTOR SUMMARY

This Quarterly Report on Form 10-Q includes “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and “forward-looking information” within the meaning of Canadian securities laws, or collectively, forward-looking statements. Forward-looking statements include statements that may relate to our plans, objectives, goals, strategies, future events, future revenue or performance, capital expenditures, financing needs and other information that is not historical information. Many of these statements appear, in particular, under the headings “Business,” “Risk Factors,” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations”. Forward-looking statements can often be identified by the use of terminology such as “subject to”, “believe,” “anticipate,” “plan,” “expect,” “intend,” “estimate,” “project,” “may,” “will,” “should,” “would,” “could,” “hope,” “can,” the negatives thereof, variations thereon and similar expressions, or by discussions of strategy. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements. Examples of such forward looking statements include, but are not limited to statements related to:

●

our ability to maintain operations, development programs, preclinical studies, clinical trials and raise capital as a result of the coronavirus disease 2019 outbreak (“COVID 19”);

●

our ability to advance our product candidate and potential future product candidates through, and successfully complete, clinical trials;

●

our ability to recruit sufficient numbers of patients in a timely manner for current and future clinical trials, and the benefits expected therefrom;

●

our ability to establish and maintain relationships with collaborators with acceptable development, regulatory and commercialization expertise and the benefits to be derived from such collaborative efforts;

●

our ability to obtain funding for operations, including research funding, and the timing and potential sources of such funding;

●

the initiation, timing, cost, location, progress and success of, strategy and plans with respect to our research and development programs (including research programs and related milestones with regards to next-generation drug candidates and compounds), preclinical studies and clinical trials;

●

the therapeutic benefits, properties, effectiveness, pharmacokinetic profile and safety of our product candidate and potential future product candidates, if any, including the expected benefits, properties, effectiveness, pharmacokinetic profile and safety of our next-generation aniten compounds;

●

our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others;

●

developments relating to our competitors and our industry, including the success of competing therapies that are or may become available;

●

our ability to achieve profitability;

●

the grant (“CPRIT Grant”) under the Cancer Prevention and Research Institute of Texas (“CPRIT”) and payments thereunder, including any residual obligations;

●

~~our ability to deal with any unknown obligation that may arise related to the acquisition of Realm Therapeutics plc (“Realm”);~~

●

our intended use of proceeds from past and future offerings of our securities;

●

the implementation of our business model and strategic plans, including strategic plans with respect to patent applications and strategic collaborations and partnerships;

●

our ability to identify, develop and commercialize product candidates;

●

our commercialization, marketing and manufacturing capabilities and strategy;

●

~~our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others;~~

●

our expectations regarding federal, state, provincial and foreign regulatory requirements, including our plans with respect to anticipated regulatory filings;

●

whether we will receive, and the timing and costs of obtaining, regulatory approvals in the United States, Canada and other jurisdictions;

●

the accuracy of our estimates of the size and characteristics of the markets that may be addressed by our product candidate and potential future product candidates, if any;

●

the rate and degree of market acceptance and clinical utility of our potential future product candidates, if any;

Table of Contents

●

the timing of, and our ability and our collaborators’ ability, if any, to obtain and maintain regulatory approvals for our product candidate and potential future product candidates, if any;

●

our expectations regarding market risk, including inflation, interest rate changes and foreign currency fluctuations;

●

our ability to engage and retain the employees required to grow our business;

●

the compensation that is expected to be paid to our employees;

●

our future financial performance and projected expenditures;

●

~~developments relating to our competitors and our industry, including the success of competing therapies that are or may become available;~~ and

●

estimates of our financial condition, expenses, future revenue, capital requirements and our need for additional financing and potential sources of capital and funding.

Such statements reflect our current views with respect to future events, are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that are inherently subject to significant medical, scientific, business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements, including those described under “Risk Factors” in our Annual Report on Form 10-K. ~~In making the~~All forward-looking statements included in this Quarterly Report on Form 10-Q, ~~we have~~are based upon our current expectations and various assumptions. Certain assumptions made ~~various material assumptions, including~~in preparing the forward-looking statements include, but are not limited to:

●

our ability to maintain operations as a result of the COVID-19 outbreak;

●

our ability to conduct a clinical study involving our product candidate and to identify any future product candidates;

●

our ability to obtain regulatory and other approvals to commence a clinical trial involving any future product candidates;

●

our ability to obtain positive results from research and development activities, including clinical trials;

●

the availability of sufficient financing on reasonable terms;

●

our ability to obtain required regulatory approvals;

●

our ability to protect patents and proprietary rights;

●

our ability to successfully out-license or sell future products, if any, and in-license and develop new products;

●

~~favorable general business and economic conditions;~~the absence of material adverse changes in our industry or the global economy;

●

our ability to attract and retain ~~skilled staff;~~key personnel;

●

~~market competition;~~our continued compliance with third party license terms and non-infringement of third-party intellectual property rights;

●

our ability to maintain good business relationships with our strategic partners; and

●

~~the products~~our ability to understand and ~~technology offered by our competitors.~~predict market competition.

We believe there is a reasonable basis for our current expectations, views and assumptions, but they are inherently uncertain. We may not realize our expectations and our views and assumptions may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements. In evaluating forward-looking statements, ~~current and prospective shareholders~~investors should specifically consider ~~various~~the following uncertainties and factors, ~~including the risks outlined~~among others (including those set forth under the heading ~~“Risk Factors”~~“Risk Factors” in our Annual Report on Form ~~10-K. Some of these risks~~10-K), that could affect future performance and ~~assumptions include, among others.~~cause actual results to differ materially from those matters expressed in or implied by forward-looking statements

●

risks related to our ability to maintain operations and execute on our business plan within projected timelines as a result of the COVID-19 outbreak or other health epidemics;

●

risks related to clinical trial development and our ability to conduct the clinical trial of our product candidate and the predictive value of our current or planned clinical trials;

●

risks related to clinical trials being conducted by third parties under collaboration and clinical supply agreements, including combination studies, using the Company’s product ~~candidate;~~candidate, studies which the Company may not control, and ensuing reputational risk related to clinical trial results;

●

risks related to our future success being dependent primarily on identification through preclinical studies, clinical studies, regulatory approval for commercialization of a single product candidate;

●

risks related to our license agreement with third parties;

●

uncertainty related to our ability to obtain required regulatory approvals for our proposed products;

Table of Contents

●

risks related to the Company’s ability to conduct a clinical trial or submit a future NDA/NDS or IND/CTA (each, as defined herein);

~~Table of Contents~~

●

~~risks related to our future ability to raise capital on favorable terms to fund the development program and the impact of dilution from any incremental financing;~~

●

risks related to our ability to successfully commercialize future product candidates;

●

risks related to the possibility that our product candidate and potential future product candidates, if any, may have undesirable side effects;

●

risks related to our ability to enroll subjects in clinical ~~trials;~~trials, including enrollment delays that may be the result of the impact of Covid at clinical trial sites;

●

risks that the FDA may not accept data from trials conducted in locations outside the United States;

●

risks related to our ongoing obligations and continued regulatory review;

●

risks related to potential administrative or judicial sanctions;

●

the risk of increased costs associated with prolonged, delayed or terminated clinical trials;

●

the risk that third parties may not carry out their contractual duties;

●

risks related to the possibility that our relationships with clinical research organizations or academic institutions may terminate;

●

risks related to our lack of experience manufacturing product candidates on a large clinical or commercial scale and our lack of manufacturing facility;

●

risks inherent in foreign operations, including related to foreign sourced raw materials, manufacturing or clinical trials;

●

risks related to disruptions in domestic and foreign supply chains that the Company relies on for the production and shipment of raw materials and clinical trial materials, including disruptions in suppliers ability to deliver related to Covid;

●

risks related to our failure to obtain regulatory approval in international jurisdictions;

●

risks related to recently enacted and future legislation in the United States that may increase the difficulty and cost for us to obtain marketing approval of, and commercialize, our product candidate and potential future products, if any, and affect the prices we may obtain;

●

risks related to new legislation, new regulatory requirements, and the continuing efforts of governmental and third-party payors to contain or reduce the costs of healthcare;

●

~~risks related~~uncertainty as to ~~any unknown obligation assumed as part of the acquisition of Realm;~~our ability to raise additional funding;

●

risks ~~that we may~~related to our ability to raise additional capital on favorable terms and the impact of dilution from incremental financing;

●

risks of a deemed default on any residual obligations of the agreement providing for the CPRIT Grant ~~which may result in us not receiving the remaining CPRIT Grant funds and/or~~and having to reimburse all of the CPRIT Grant, if such deemed default is not waived by CPRIT;

●

risks related to our incurrence of significant losses in every quarter since inception and our anticipation that it will continue to incur significant losses in the future;

●

risks related to our limited operating history;

●

risks related to our reliance on proprietary technology;

●

risks related to our ability to protect our intellectual property rights throughout the world;

●

risks related to claims by third parties asserting that we, or our employees or consultants have misappropriated their intellectual property, or claiming ownership of what we regard as our intellectual property;

●

risks related to our ability to comply with governmental patent agency requirements in order to maintain patent protection;

●

risks related to computer system failures or security ~~breaches;~~breaches and increasing cyber threats;

●

risks related to business disruptions that could seriously harm our future revenues and financial condition and increase our costs and expenses;

●

risks related to our dependence on the use of information technologies;

●

risks related to our ability to attract and maintain ~~highly-qualified~~highly qualified personnel;

●

risks relating to the possibility that third-party coverage and reimbursement and health care cost containment initiatives and treatment guidelines may constrain our future revenues;

●

risks related to potential conflicts of interest between us and our directors and officers;

●

risks related to competition from other biotechnology and pharmaceutical companies;

●

risks related to movements in foreign currency exchange rates, interest rates and rate of inflation;

Table of Contents

●

risks related to our ability to convince public payors and hospitals to include our product candidate and potential future products, if any, on their approved formulary lists;

●

risks related to our ability to establish an effective sales force and marketing infrastructure, or enter into acceptable third-party sales and marketing or licensing arrangements;

●

risks related to our ability to manage growth;

●

risks related to our ability to achieve or maintain expected levels of market acceptance for our products;

●

risks related to our ability to realize benefits from acquired businesses or products or form strategic alliances in the future;

~~Table of Contents~~

●

risks related to collaborations with third parties;

●

risks that employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could cause significant liability for us and harm our reputation;

●

risks related to product liability lawsuits;

●

risks related to compulsory licensing and/or generic competition;

●

risks ~~inherent in foreign operations, including~~ related to ~~foreign sourced raw materials, manufacturing or clinical trials;~~no longer being considered an emerging growth company;

●

risks related to ~~disruptions in domestic and foreign supply chains that the Company relies on~~our ability to maintain an active trading market for the ~~production and shipment~~Company's common shares;

●

risks related to share price volatility in the event there is low liquidity for the trading of ~~raw materials and clinical trial materials;~~the Company’s common shares;

●

risks related to the possibility that laws and regulations governing international operations may preclude us from developing, manufacturing and selling certain product candidates outside of the United States and Canada and require us to develop and implement costly compliance programs;

●

risks related to laws that govern fraud and abuse and patients’ rights;

●

risks related to our ability to comply with environmental, health and safety laws and regulations;

●

risks related to us being a “passive foreign investment company”;

●

risks related to ~~the Company’s status as an emerging growth company and in the future as an accelerated filer;~~

●

~~risks related to~~ United States investors’ ability to effect service of process or enforcement of actions against us;

●

~~risks related to our ability to maintain compliance with Nasdaq listing requirements;~~

●

~~risks related to any impact on the Company by activities of investors who are Section 16 filers;~~

●

risks related to market price and trading volume volatility;

●

risks related to our dividend policy;

●

risks associated with future sales of our securities;

●

risks related to our ability to implement and maintain effective internal controls;

●

risks related to ~~share price volatility~~provisions in ~~the event there is low liquidity for the trading of the Company’s common shares;~~our charter documents and Canadian law affecting corporate governance; and

●

risks related to analyst coverage.

If one or more of these risks or uncertainties or a risk that is not currently known to us, materialize, or if our underlying assumptions prove to be incorrect, actual results may vary ~~significantly~~materially from those expressed or implied by forward-looking statements. The forward-looking statements represent our expectations, plans, estimates and views as of the date of this document. ~~While we may elect~~We do not undertake and specifically decline any obligation to update, ~~these~~republish or revise forward-looking statements into reflect future events or circumstances or to reflect the ~~future, we have no current intention to do so~~occurrences of unanticipated events, except as ~~to the extent~~ required by ~~applicable securities~~ law. Investors are cautioned that we cannot guarantee future results, events, levels of activity, performance or achievements and that forward-looking statements ~~are not guarantees of future performance and~~ are inherently uncertain. Accordingly, investors are cautioned not to put undue reliance on forward-looking statements. We advise you that these cautionary remarks expressly qualify in their entirely all forward-looking statements attributable to us or persons acting on our behalf.

Table of Contents

In December 2019, a novel strain of coronavirus, COVID-19, was reported to have surfaced in Wuhan, China. Since then, COVID-19 has spread to multiple countries, including the United States, Canada, and all European countries. On March 11, 2020, the World Health Organization characterized COVID-19 as a pandemic. COVID-19 has had a broad adverse impact on the global economy across many industries and has resulted in significant governmental measures being implemented to control the spread of the virus, including quarantines, travel restrictions and business shutdowns, as well as significant volatility in global financial markets. Although COVID-19 has not ~~yet~~to date had ~~any~~a material impact on our business, operations, or financial condition, there can be no assurances that it will not have an impact on our business, operations, or financial condition going ~~forward.~~forward, such as disruption to supply chains or in the recruitment of patients at clinical trial sites, which has resulted in delays to projected timelines that are not deemed to be material. Management has taken recommended precautions, including adherence to local and facility-related pandemic mandates, support for work at home, encouragement and monitoring of employee vaccination, implementation of changes to secure supply chains, and taking other steps to minimize the impact to the Company of the effect of COVID-19 on vendors and partners involved in the clinical trial program, including engaging additional clinical trial sites. See “~~Risk~~“Risk Factors - Risks Relating to ~~COVID-19~~”COVID-19” in our Annual Report on Form 10-K.

We express all amounts in this Quarterly Report on Form 10-Q in U.S. dollars, except where otherwise indicated. References to “$” and “US$” are to U.S. dollars and references to “C$” are to Canadian dollars. Except as otherwise indicated, references in this Quarterly Report on Form 10-Q to “ESSA,” “the Company,” “we,” “us” and “our” refer to ESSA Pharma Inc. and its subsidiaries.

Table of Contents

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements and Supplementary Data

ESSA Pharma Inc.

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

(Unaudited)

(Expressed in United States dollars)

FOR THE THREE AND ~~NINE~~SIX MONTHS ENDED ~~JUNE 30, 2021~~MARCH 31, 2022

Table of Contents

ESSA PHARMA INC.

CONDENSED CONSOLIDATED INTERIM BALANCE SHEETS

(Unaudited)

(Expressed in United States dollars)

AS OF


		June 30,		September 30,		March 31,		September 30,
	2021		2020		2022		2021

ASSETS

Current
Cash and cash equivalents	$	145,194,181	$	56,320,763	$	86,235,830	$	137,825,024
Short-term investments (Note 4)		57,068,822		22,011,337		94,782,609		57,102,159
Receivables		231,146		309,538		19,254		489,012
Prepaids (Note 5)		463,789		1,600,128		1,064,464		2,181,882
Operating lease right-of-use assets (Note 7)		0		55,162

		202,957,938		80,296,928		182,102,157		197,598,077

Deposits		268,574		277,637		259,455		259,455
Operating lease right-of-use assets (Note 7)		297,533		0		247,393		308,286

Total assets	$	203,524,045	$	80,574,565	$	182,609,005	$	198,165,818

LIABILITIES AND SHAREHOLDERS’ EQUITY

Current
Accounts payable and accrued liabilities (Note 6)	$	2,910,964	$	1,144,230	$	3,618,508	$	3,808,944
Current portion of operating lease liability (Note 7)		97,763		59,094
Current portion of operating lease liabilities (Note 7)						128,366		120,719
Current portion of derivative liabilities (Note 8)						1,929		0

		3,008,727		1,203,324		3,748,803		3,929,663

Derivative liabilities (Note 9)		597,508		127,376
Operating lease liability (Note 7)		220,227		0
Operating lease liabilities (Note 7)						145,268		210,251
Derivative liabilities (Note 8)						0		20,352

Total liabilities		3,826,462		1,330,700		3,894,071		4,160,266

Shareholders’ equity
Authorized
Unlimited common shares, without par value
Unlimited preferred shares, without par value
Common shares 41,854,916 issued and outstanding (September 30, 2020 – 32,064,411) (Note 10)		277,370,996		131,086,364
Additional paid-in capital (Note 10)		33,619,332		31,204,284
Common shares 44,059,700 issued and outstanding (September 30, 2021 – 43,984,346) (Note 9)						278,029,966		277,415,176
Additional paid-in capital (Note 9)						40,538,466		36,442,620
Accumulated other comprehensive loss		(2,076,479)		(2,076,479)		(2,125,210)		(2,076,479)
Accumulated deficit		(109,216,266)		(80,970,304)		(137,728,288)		(117,775,765)

		199,697,583		79,243,865		178,714,934		194,005,552

Total liabilities and shareholders’ equity	$	203,524,045	$	80,574,565	$	182,609,005	$	198,165,818

~~Subsequent events~~Nature of operations (Note ~~14)~~1)

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

Table of Contents

ESSA PHARMA INC.

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(Unaudited)

(Expressed in United States dollars)

For the three months ended

For the nine months ended

June 30,

June 30,


2021

2020

2021

2020

OPERATING EXPENSES








Research and development

$
6,231,908

$
2,703,704

$
17,985,937

$
9,909,288
Financing costs (Notes 7 and 8)

16,667

197,102

18,147

500,972
General and administration

3,117,900

2,171,020

9,942,149

9,173,793

Total operating expenses

(9,366,475)

(5,071,826)

(27,946,233)

(19,584,053)

Foreign exchange

(34,084)

10,937

(19,239)

(685)
Interest income

80,394

172,346

155,293

478,952
Derivative liability gain (loss) (Note 9)

568,954

(36,285)

(470,132)

(60,242)

Loss for the period before taxes

(8,751,211)

(4,924,828)

(28,280,311)

(19,166,028)

Income tax recovery (expense)

(800)

0

34,349

274,000

Loss and comprehensive loss for the period

$
(8,752,011)

$
(4,924,828)

$
(28,245,962)

$
(18,892,028)

Basic and diluted loss per common share

$
(0.21)

$
(0.24)

$
(0.76)

$
(0.91)

Weighted average number of common shares outstanding – basic and diluted

41,018,024

20,824,568

36,937,014

20,802,026



	For the three months ended				For the six months ended
	March 31,				March 31,
	2022		2021		2022		2021

OPERATING EXPENSES
Research and development	$	7,649,459	$	7,268,257	$	13,669,218	$	11,754,029
Financing costs (Note 7)		3,526		299		7,851		1,480
General and administration		3,817,370		4,615,332		6,879,540		6,824,249

Total operating expenses		(11,470,355)		(11,883,888)		(20,556,609)		(18,579,758)

Foreign exchange		16,259		7,649		29,428		14,845
Interest and other income		481,751		39,208		556,335		74,899
Derivative liability gain (loss) (Note 8)		117,741		(1,128,216)		18,423		(1,039,086)

Net loss for the period before taxes		(10,854,604)		(12,965,247)		(19,952,423)		(19,529,100)

Income tax recovery (expense)		—		—		(100)		35,149

Net loss for the period		(10,854,604)		(12,965,247)		(19,952,523)		(19,493,951)

OTHER COMPREHENSIVE LOSS
Unrealized loss on short-term investments		(48,731)		—		(48,731)		—

Loss and comprehensive loss for the period	$	(10,903,335)	$	(12,965,247)	$	(20,001,254)	$	(19,493,951)

Basic and diluted loss per common share	$	(0.25)	$	(0.36)	$	(0.45)	$	(0.56)

Weighted average number of common shares outstanding – basic and diluted		44,030,480		36,484,041		44,009,903		34,896,509

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

910

Table of Contents

ESSA PHARMA INC.

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS

(Unaudited)

(Expressed in United States dollars)

FOR THE ~~NINE~~SIX MONTHS ENDED ~~JUNE 30,~~MARCH 31,



	2021		2020		2022		2021

CASH FLOWS FROM OPERATING ACTIVITIES
Loss for the period	$	(28,245,962)	$	(18,892,028)	$	(19,952,523)	$	(19,493,951)
Items not affecting cash and cash equivalents:
Amortization of right-of-use asset		80,665		82,743		60,893		55,162
Amortization of premiums/discounts on short-term investments, net						65,060		0
Accretion of lease liability		5,497		10,893		7,410		1,480
Derivative liability loss		470,132		60,242
Derivative liability loss (gain)						(18,423)		1,039,086
Interest income		(42,719)		0		(157,464)		(20,106)
Finance expense		0		211,079
Unrealized foreign exchange		26,497		15,396		19,520		23,300
Share-based payments		6,652,613		6,347,186		4,363,444		3,868,671
Income tax recovery		0		(278,000)

Changes in non-cash working capital items:
Receivables		104,749		12,971		476,062		19,246
Prepaids		1,145,402		(297,467)		1,117,418		1,108,166
Accounts payable and accrued liabilities		1,770,800		(83,185)		(186,188)		1,883,888
Income tax payable		0		(22,000)

Net cash used in operating activities		(18,032,326)		(12,832,170)		(14,204,791)		(11,515,058)

CASH FLOWS FROM INVESTING ACTIVITIES

Purchase of short-term investments		(57,026,103)		0		(104,817,397)		(55,017,103)
Proceeds from short-term investments sold		22,000,000		0		67,028,803		20,000,000
Interest from short-term investments		11,337		0		162,789		13,625

Net cash used in investing activities		(35,014,766)		0		(37,625,805)		(35,003,478)

CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds on issuance of common shares		149,999,985		0		0		149,999,985
Share issuance costs		(9,229,451)		(314,603)		0		(9,109,462)
Options exercised		1,186,833		915		319,832		930,686
Warrants exercised		382		247,864		0		249
Shares purchased through employee share purchase plan		89,318		80,714		27,360		27,369
Lease payments		(69,637)		(89,096)		(64,746)		(60,575)
Loan principal repaid		0		(3,199,799)
Loan final payment paid		0		(688,000)
Interest and financing costs paid		0		(32,235)

Net cash provided by (used in) financing activities		141,977,430		(3,994,240)
Net cash provided by financing activities						282,446		141,788,252

Effect of foreign exchange on cash and cash equivalents		(56,920)		(14,264)		(41,044)		(28,176)

Change in cash and cash equivalents for the period		88,873,418		(16,840,674)		(51,589,194)		95,241,540

Cash and cash equivalents, beginning of period		56,320,763		53,322,723		137,825,024		56,320,763

Cash and cash equivalents, end of period	$	145,194,181	$	36,482,049	$	86,235,830	$	151,562,303

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

1011

Table of Contents

ESSA PHARMA INC.

CONDENSED CONSOLIDATED INTERIM STATEMENT OF CHANGES IN SHAREHOLDERS’ EQUITY

(Unaudited)

(Expressed in United States dollars)

FOR THE THREE AND ~~NINE~~SIX MONTHS ENDED ~~JUNE 30,~~MARCH 31, 2022 AND 2021 ~~and 2020~~


								Accumulated
				Obligation		Additional		other
	Number	Common		to issue		paid-in		comprehensive
	of shares	shares		shares		capital		loss		Deficit		Total

Balance, September 30, 2019	20,762,374	$	78,545,108	$	—	$	30,038,134	$	(2,076,479)	$	(57,524,934)	$	48,981,829
Share issuance costs	—		(3,598)		—		(7,054)		—		—		(10,652)
Warrants exercised	—		—		227,864		—		—		—		227,864
Share-based payments	—		—		—		1,253,621		—		—		1,253,621
Loss for the period	—		—		—		—		—		(4,613,273)		(4,613,273)

Balance, December 31, 2019	20,762,374	$	78,541,510	$	227,864	$	31,284,701	$	(2,076,479)	$	(62,138,207)	$	45,839,389
Options exercised	61,965		422,195		(227,864)		(174,331)		—		—		20,000
Share-based payments	—		—		—		3,584,617		—		—		3,584,617
Loss for the period	—		—		—		—		—		(9,353,927)		(9,353,927)

Balance, March 31, 2020	20,824,339	$	78,963,705	$	—	$	34,694,987	$	(2,076,479)	$	(71,492,134)	$	40,090,079
Options exercised	416		1,648		—		(733)		—		—		915
Shares issued through employee share purchase plan	16,506		136,926		—		(56,212)		—		—		80,714
Share-based payments	—		—		—		1,508,948		—		—		1,508,948
Loss for the period	—		—		—		—		—		(4,924,828)		(4,924,828)

Balance, June 30, 2020	20,841,261	$	79,102,279	$	—	$	36,146,990	$	(2,076,479)	$	(76,416,962)	$	36,755,828

								Accumulated											Accumulated
				Obligation		Additional		other									Additional		other
	Number	Common		to issue		paid-in		comprehensive						Number	Common		paid-in		comprehensive
	of shares	shares		shares		capital		loss		Deficit		Total		of shares	shares		capital		loss		Deficit		Total

Balance, September 30, 2020	32,064,411	$	131,086,364	$	—	$	31,204,284	$	(2,076,479)	$	(80,970,304)	$	79,243,865	32,064,411	$	131,086,364	$	31,204,284	$	(2,076,479)	$	(80,970,304)	$	79,243,865
Warrants exercised	1,493,504		2,987,158		—		(2,987,009)		—		—		149	1,493,504		2,987,158		(2,987,009)		—		—		149
Options exercised	42,207		274,365		—		(120,664)		—		—		153,701	42,207		274,365		(120,664)		—		—		153,701
Shares issued through employee share purchase plan	5,261		39,638		—		(12,269)		—		—		27,369	5,261		39,638		(12,269)		—		—		27,369
Share-based payments	—		—		—		1,204,985		—		—		1,204,985	—		—		1,204,985		—		—		1,204,985
Loss for the period	—		—		—		—		—		(6,528,704)		(6,528,704)	—		—		—		—		(6,528,704)		(6,528,704)

Balance, December 31, 2020	33,605,383	$	134,387,525	$	—	$	29,289,327	$	(2,076,479)	$	(87,499,008)	$	74,101,365	33,605,383	$	134,387,525	$	29,289,327	$	(2,076,479)	$	(87,499,008)	$	74,101,365
Financing	5,555,555		149,999,985		—		—		—		—		149,999,985	5,555,555		149,999,985		—		—		—		149,999,985
Share issuance costs	—		(9,168,801)		—		—		—		—		(9,168,801)	—		(9,168,801)		—		—		—		(9,168,801)
Warrants exercised	1,043,538		143,853		—		(143,753)		—		—		100	1,043,538		143,853		(143,753)		—		—		100
Options exercised	213,381		1,377,947		—		(600,962)		—		—		776,985	213,381		1,377,947		(600,962)		—		—		776,985
Share-based payments	—		—		—		2,663,684		—		—		2,663,684	—		—		2,663,684		—		—		2,663,684
Loss for the period	—		—		—		—		—		(12,965,247)		(12,965,247)	—		—		—		—		(12,965,247)		(12,965,247)

Balance, March 31, 2021	40,417,857	$	276,740,509	$	—	$	31,208,296	$	(2,076,479)	$	(100,464,255)	$	205,408,071	40,417,857	$	276,740,509	$	31,208,296	$	(2,076,479)	$	(100,464,255)	$	205,408,071

Share issuance costs	—		(60,649)		—		—		—		—		(60,649)
Warrants exercised	1,362,765		123,023		—		(122,890)		—		—		133

																			Accumulated
																	Additional		other
														Number	Common		paid-in		comprehensive
														of shares	shares		capital		loss		Deficit		Total

Balance, September 30, 2021														43,984,346	$	277,415,176	$	36,442,620	$	(2,076,479)	$	(117,775,765)	$	194,005,552
Options exercised	68,022		453,155		—		(197,008)		—		—		256,147	29,080		184,512		(80,188)		—		—		104,324
Shares issued through employee share purchase plan	6,272		114,958		—		(53,010)		—		—		61,948	2,444		45,936		(18,576)		—		—		27,360
Share-based payments	—		—		—		2,783,944		—		—		2,783,944	—		—		2,500,091		—		—		2,500,091
Loss for the period	—		—		—		—		—		(8,752,011)		(8,752,011)	—		—		—		—		(9,097,919)		(9,097,919)

Balance, June 30, 2021	41,854,916	$	277,370,996	$	—	$	33,619,332	$	(2,076,479)	$	(109,216,266)	$	199,697,583
Balance, December 31, 2021														44,015,870	$	277,645,624	$	38,843,947	$	(2,076,479)	$	(126,873,684)	$	187,539,408
Options exercised														43,830		384,342		(168,834)		—		—		215,508
Share-based payments														—		—		1,863,353		—		—		1,863,353
Loss for the period														—		—		—		(48,731)		(10,854,604)		(10,903,335)

Balance, March 31, 2022														44,059,700	$	278,029,966	$	40,538,466	$	(2,125,210)	$	(137,728,288)	$	178,714,934

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

1112

Table of Contents

ESSA PHARMA INC.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

(Unaudited)

(Expressed in United States dollars)

FOR THE ~~NINE~~SIX MONTHS ENDED ~~JUNE 30, 2021~~MARCH 31, 2022

1. NATURE OF OPERATIONS

Nature of Operations

The Company was incorporated under the laws of the Province of British Columbia on January 6, 2009. The Company’s head office address is Suite 720 – 999 West Broadway, Vancouver, BC, V5Z 1K5. The registered and records office address is the 26^th Floor at 595 Burrard Street, Three Bentall Centre, Vancouver, BC, V7X 1L3. The Company is listed on the Nasdaq Capital Market (“Nasdaq”) under the symbol “EPIX”. ~~On October 30, 2020 the Company’s common shares delisted in Canada from the TSX Venture Exchange.~~

The Company is focused on the development of small molecule drugs for the treatment of prostate cancer. The Company has acquired a license to certain patents (“NTD”) which were the joint property of the British Columbia Cancer Agency and the University of British Columbia. As of ~~June 30, 2021,~~March 31, 2022, no products are in commercial production or use.

2. BASIS OF PRESENTATION

Basis of Presentation

These accompanying unaudited condensed consolidated interim financial statements, including comparatives, have been prepared in accordance with United States’ Generally Accepted Accounting Principles (“U.S. GAAP”) and pursuant to the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, these condensed consolidated interim financial statements do not include all of the information and footnotes required for complete consolidated financial statements and should be read in conjunction with the audited consolidated financial statements and notes for the year ended September 30, ~~2020~~2021 and included in the Company’s ~~2020~~2021 Annual Report on Form 10-K filed with the SEC and with the securities commissions in British Columbia, Alberta and Ontario on ~~December 15, 2020.~~November 18, 2021.

These unaudited condensed consolidated interim financial statements reflect all adjustments, consisting of normal recurring adjustments, which, in the opinion of management, are necessary for a fair presentation of results for the interim periods presented. The results of operations for the ~~nine~~three months ended ~~June 30,~~March 31, 2022 and 2021 ~~and 2020~~ are not necessarily indicative of results that can be expected for a full year. These unaudited condensed consolidated interim financial statements follow the same significant accounting policies as those described in the notes to the audited consolidated financial statements of the Company included in the Company’s ~~2020~~2021 Annual Report on Form 10-K for the year ended September 30, ~~2020,~~2021, with the exception of ~~the~~any policies described in Note 3.

These accompanying unaudited condensed consolidated interim financial statements include the accounts of the Company and its wholly owned subsidiaries. Inter-company transactions, balances and unrealized gains or losses on transactions are eliminated upon consolidation.

The accompanying condensed consolidated interim financial statements have been prepared on a historical cost basis except for certain financial assets measured at fair value.

All amounts expressed in these accompanying condensed consolidated interim financial statements and the accompanying notes are expressed in United States dollars, except per share data and where otherwise indicated. References to “$” are to United States dollars and references to “C$” are to Canadian dollars.

1213

Table of Contents

Use of Estimates

The preparation of the accompanying condensed consolidated interim financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions about future events that affect the reported amounts of assets, liabilities, expenses, contingent assets and contingent liabilities as of the end of, or during, the reporting period. Actual results could significantly differ from those estimates. Significant areas requiring management to make estimates include the derivative liabilities, the valuation of equity instruments issued for services, income taxes and the product development and relocation grant. Further details of the nature of these assumptions and conditions may be found in the relevant notes to these condensed consolidated interim financial statements.

The effect of a change in an accounting estimate is recognized prospectively by including it in comprehensive income in the period of the change, if the change affects that period only, or in the period of the change and future periods, if the change affects both. Estimates and assumptions are reviewed quarterly.

3. RECENT ACCOUNTING PRONOUNCEMENTS

Recent accounting pronouncements not yet adopted

~~ASU 2018-18 – Collaborative Arrangements (Topic 808)~~

~~In November 2018, the FASB~~Management does not believe that any recently issued, ASU 2018-18, “Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606”. This ASU: (i) clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606 when the collaborative arrangement participant is a customer, (ii) provides guidance specifying that a distinct good or service is the unit of account for evaluating whether a transaction is with a customer, and (iii) precludes a company from presenting transactions with a collaborative arrangement participant that arebut not ~~in the scope of ASC 606 together with revenue from contracts with customers. This ASU is~~yet effective, ~~for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. The Company~~accounting standards, if currently adopted, ~~this accounting standard as of October 1, 2020. The Company will present collaboration revenue separate from product revenues. The adoption of this new accounting standard did not~~would have a ~~significant impact on the Company’s consolidated financial statements.~~

~~ASU 2018-15 – Intangibles – Goodwill and Other (Subtopic 350-40)~~

In August 2018, the FASB issued ASU 2018–15, Intangibles - Goodwill and Other - Internal Use Software (Subtopic 350–40). This ASU addresses the accounting for implementation costs incurred by a customer in a cloud computing arrangement that is a service contract and also adds certain disclosure requirements related to implementation costs incurred for internal-use software and cloud computing arrangements. The amendment aligns the requirements for capitalizing implementation costs incurred in a cloud computing arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). This ASU is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. The Company adopted this accounting standard as of October 1, 2020 and has applied it prospectively to all implementation costs incurred after October 1, 2020. The adoption of this new accounting standard did not have a significant impact on the Company’s consolidated financial statements.

~~Table of Contents~~

~~ASU 2018-13 – Fair Value Measurement (Topic 820-10)~~

In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820-10): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement (“ASU 2018-13”), which changes the fair value measurement disclosure requirements of ASC Topic 820, Fair Value Measurements and Disclosures. Under this ASU, certain disclosure requirements for fair value measurements are eliminated, amended or added. These changes aim to improve the overall usefulness of disclosures to financial statement users and reduce unnecessary costs to companies when preparing the disclosures. The Company has adopted this standard as of October 1, 2020. The adoption of the standard had no impact on the Company’s consolidated financial statements and disclosures.

~~ASU 2019-12 – Income Taxes (Topic 740)~~

In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which simplifies the accounting for income taxes by removing certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new ASU also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates. These changes aim to improve the overall usefulness of disclosures to financial statement users and reduce unnecessary costs to companies when preparing the disclosures. The Company has adopted this standard as of October 1, 2020. The adoption of the standard had no impactmaterial effect on the Company’s condensed consolidated interim financial ~~statements and disclosures.~~

~~ASU 2016-13 – Financial Instruments-Credit Losses (Topic 326)~~

In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost, including trade receivables. ASU 2016-13 replaces the existing incurred loss impairment model with an expected loss model that requires the use of forward-looking information to calculate credit loss estimates. This guidance is effective for annual reporting periods beginning after December 15, 2019, with early adoption permitted. The Company has adopted this standard as of October 1, 2020. The adoption of the standard had no impact on the Company’s condensed consolidated interim financial statements and disclosures.

~~Recent accounting pronouncements not yet adopted~~

~~ASU 2020-06~~ ~~– Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40)~~

In August 2020, the FASB issued ASU No. 2020-06 (“ASU 2020-06”) “Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity.” ASU 2020-06 will simplify the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models will result in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. ASU 2020-06 also amends the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. ASU 2020-06 will be effective January 1, 2024, for the Company. Early adoption is permitted, but no earlier than January 1, 2021, including interim periods within that year. Management is currently evaluating the effect of the adoption of ASU 2020-06 on the consolidated financial statements, but currently does not believe ASU 2020-06 will have a significant impact on the Company’s accounting.

~~Table of Contents~~

~~ASU 2020-10 – Codification Improvements~~

In October 2020, the FASB issued ASU 2020-10, Codification Improvements. The guidance contains improvements to the Codification by ensuring that all guidance that requires or provides an option for an entity to provide information in the notes to financial statements is codified in the Disclosure Section of the Codification. The guidance also contains Codifications that are varied in nature and may affect the application of the guidance in cases in which the original guidance may have been unclear. For public business entities, the amendments in the ASU are effective for fiscal years beginning after December 15, 2020. For all other entities, the amendments are effective for annual periods beginning after December 15, 2021, and interim periods within annual periods beginning after December 15, 2022. Early adoption is permitted. We do not expect the adoption of ASU 2020-10 to have a material impact on our condensed consolidated financial statements.

~~ASU 2021-04 – Earnings per share~~

In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40). The new ASU addresses issuer’s accounting for certain modifications or exchanges of freestanding equity-classified written call options. This amendment is effective for all entities, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted. The Company will evaluate the impact of the pronouncement closer to the effective date.

Recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statement presentation or disclosures.

~~4. SHORT-TERM INVESTMENTS~~

Short-term investments consist of guaranteed investment certificates (“GICs”) held at financial institutions purchased in accordance with the Company’s treasury policy. These GICs and term deposits bear interest at 0.22%-0.40% per annum and have maturities of up to 12 months.

~~5. PREPAIDS~~

June 30,

September 30,

2021

2020

Prepaid insurance

$
149,179

$
825,014
Prepaid CMC and clinical expenses and deposits

126,000

650,586
Other deposits and prepaid expenses

188,610

124,528

Balance, end of period

$
463,789

$
1,600,128

~~6. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES~~

June 30,

September 30,

2021

2020

Accounts payable

$
907,537

$
678,643
Accrued expenses

1,702,793

310,604
Accrued vacation

300,634

154,983

Balance, end of period

$
2,910,964

$
1,144,230

1514

Table of Contents

4. SHORT-TERM INVESTMENTS

Short-term investments consist of guaranteed investment certificates (“GICs”) held at financial institutions purchased in accordance with the Company’s treasury policy. These GICs and term deposits bear interest at 0.31%-1.58% per annum and have maturities of up to 12 months.

Short-term investments also consist of U.S. treasury securities, corporate debt securities and commercial paper. The Company has classified these investments as available-for-sale, as the sale of such investments may be required prior to maturity to implement management strategies, and therefore has classified all investment securities as current assets. Those investments with maturity dates of three months or less at the date of purchase are presented as cash equivalents in the accompanying balance sheets. Short-term investments are carried at fair value with the unrealized gains and losses included in accumulated other comprehensive loss as a component of shareholders’ equity (deficit) until realized. Any premium or discount arising at purchase is amortized or accreted to interest income as an adjustment to yield using the straight-line method over the life of the instrument. The Company records an allowance for credit losses when unrealized losses are due to credit-related factors. Realized gains and losses are calculated using the specific identification method and recorded as interest income.


		As of March 31, 2022
		Amortized	Unrealized					Accrued		Estimated
		Cost		Gains		Losses		Interest		Fair Value

GICs and Term deposits	$	77,171,949	$	—	$	—	$	20,918	$	77,192,867
U.S. Treasury securities		11,266,180		—		(25,478)		121,842		11,362,544
Corporate debt securities		5,220,823		—		(21,024)		30,444		5,230,243
Commercial paper		996,955		—		—		—		996,955

Balance, end of period	$	94,655,907	$	—	$	(46,502)	$	173,204	$	94,782,609

		As of September 30, 2021
		Amortized	Unrealized					Accrued		Estimated
		Cost		Gains		Losses		Interest		Fair Value

GICs and Term deposits	$	57,026,103	$	—	$	—	$	76,056	$	57,102,159

Balance, end of period	$	57,026,103	$	—	$	—	$	76,056	$	57,102,159

As of March 31, 2022, short-term investments have an aggregate fair market value of $94.8 million (2021 – $57.1 million) were in an aggregate gross unrealized loss position of $46,502 (2021 - $Nil). The Company considers the decline in market value for the securities to be primarily attributable to current economic and market conditions. These particular investments have been in an unrealized loss position for less than 12 months and it is not more likely than not that the Company will be required to sell any of its securities prior to maturity. Accordingly, no allowance for credit losses has been recorded as of March 31, 2022 and 0 realized gains or losses on sales of short-term investments have been recorded through March 31, 2022.

Table of Contents

5. PREPAIDS


		March 31,		September 30,
	2022		2021

Prepaid insurance	$	800,780	$	1,751,052
Prepaid CMC and clinical expenses and deposits		240,513		240,513
Other deposits and prepaid expenses		23,171		190,317

Balance, end of period	$	1,064,464	$	2,181,882

6. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES


		March 31,		September 30,
	2022		2021

Accounts payable	$	756,555	$	1,425,871
Accrued expenses		2,485,360		2,062,441
Accrued vacation		376,593		320,632

Balance, end of period	$	3,618,508	$	3,808,944

7. OPERATING LEASE

~~The Company has one operating lease for the South San Francisco office extended from April 1, 2021 to May 31, 2024. The Company’s operating leases included on the balance sheet are as follows:~~


Operating lease right-of-use asset
Balance, September 30, 2020	$	55,162
Addition		341,125
Amortization		(55,162)

Balance, March 31, 2021	$	341,125

Balance, September 30, 2021	$	308,286
Amortization		(60,893)

Balance, March 31, 2022	$	247,393


Operating lease liabilities
Balance, September 30, 2020	$	59,094
Addition		341,125
Accretion		1,480
Lease payments		(60,574)

Balance, March 31, 2021	$	341,125

Balance, September 30, 2021	$	330,970
Accretion		7,410
Lease payments		(64,746)

Balance, March 31, 2022	$	273,634

Operating lease right-of-use asset



Balance, September 30, 2019

$
0
Adoption of ASC 842

165,486
Amortization

(82,743)

Balance, June 30, 2020

$
82,743

Balance, September 30, 2020

$
55,162
Addition

323,036
Amortization

(80,665)

Balance, June 30, 2021

$
297,533

Operating lease liabilities


Balance, September 30, 2019

$
0
Adoption of ASC 842

165,486
Accretion

10,893
Lease payments

(89,096)

Balance, June 30, 2020

$
87,283

Balance, September 30, 2020

$
59,094
Addition

323,036
Accretion

5,497
Lease payments

(69,637)

Balance, June 30, 2021

$
317,990

Table of Contents

The Company recognizes a right-of-use asset for the right to use the underlying asset for the lease term, and a lease liability, which represents the present value of the Company’s obligation to make payments over the lease term. The present value of the lease payments is calculated using an incremental borrowing rate as the Company’s leases do not provide an implicit interest rate. At ~~June 30, 2021,~~March 31, 2022, the Company’s incremental borrowing rate was 5.0% and the remaining lease term for the South San Francisco office was ~~extended by 38~~26 months and Houston office was 16 months.

~~Operating lease costs of $69,637 (2020 - $89,096) and accretion~~Accretion expense of ~~$5,497 (2020~~$7,410 (2021 - ~~$10,893) have~~$1,480) has been recorded in “general and administrative expenses” and “financing costs” in the condensed consolidated interim statements of operations and comprehensive loss respectively.

~~8. LONG-TERM DEBT~~

On November 18, 2016, Silicon Valley Bank (“SVB”) entered into a $10,000,000 capital term loan facility agreement (“SVB Term Loan”) with the Company. The Company drew down $8,000,000 from the SVB Term Loan. The option to draw an additional $2,000,000 lapsed on July 31, 2017. In the year ended September 30, 2020, the Company repaid the balance owing for $3,708,955, comprising $3,199,799 in principal, $32,235 in accrued interest, $211,079 in financing costs and the Final Payment of $688,000.

~~Table of Contents~~

9.8. DERIVATIVE LIABILITIES

In January 2016, the Company completed a private placement of 227,273 units of the Company at $66.00 per unit (“Unit”) for gross proceeds of $14,999,992. Each Unit consisted of 1 common share of the Company, 1 7-year cash and cashless exercise warrant (the “7-Year Warrants”), and one half of one 2-year cash exercise warrant (the “2-Year Warrants”). The 7-Year Warrants and 2-Year Warrants have an exercise price of $66.00 per common share (collectively, the “2016 Warrants”). The holders of the 7-Year Warrants may elect, in lieu of exercising the 7-Year Warrants for cash, a cashless exercise option, in whole or in part, to receive common shares equal to the fair value of the 7-Year Warrants based on the number of 7-Year Warrants to be exercised multiplied by a ten-day weighted average market price less the exercise price with the difference divided by the weighted average market price. If a warrant holder exercises this option, there will be variability in the number of shares issued per 7-Year Warrant.

Additionally, the 2016 Warrants contain provisions which may require the Company to redeem the 2016 Warrants, at the option of the holder, in the event of a major transaction, such as a change of control or sale of the Company’s assets (“Major Transaction”). The redemption value would be subject to a Black-Scholes valuation at the time of exercise. In the event the consideration for a Major Transaction payable to the common shareholders is in cash, in whole or in part, the redemption of the 2016 Warrants would be made in cash pro-rata to the composition of the consideration. The potential for a cash settlement for the 2016 Warrants outside the control of the Company, in accordance with U.S. GAAP, requires the 2016 Warrants to be treated as financial liabilities measured at fair value through profit or loss. The 2016 Warrants are not traded in an active market.

Valuation

The Company uses the Black-Scholes option pricing model to estimate fair value. The following weighted average assumptions were used to estimate the fair value of the derivative warrant liabilities on ~~June 30, 2021~~March 31, 2022 and ~~2020:~~2021:



	June 30,		June 30,		March 31,		March 31,
	2021		2020		2022		2021

Risk-free interest rate	0.36	%	0.23	%	2.65	%	0.29	%
Expected life	1.54	years	2.54	years	0.79	years	1.79	years
Expected annualized volatility	70.8	%	86.9	%	93.6	%	85.9	%
Dividend	0		0		0		0
Liquidity discount	20	%	20	%	20	%	20	%

Table of Contents

Sensitivity

The derivative warrants are a recurring Level 3 fair value measurement. The key level 3 inputs used by management to determine the fair value are the market price, expected volatility and liquidity discount. If the market price were to increase by a factor of 10% this would increase the obligation by approximately ~~$206,222~~$1,039 as of ~~June 30, 2021.~~March 31, 2022. If the market price were to decrease by a factor of 10% this would decrease the obligation by approximately ~~$186,074~~$747 as of ~~June 30, 2021.~~March 31, 2022. If the volatility were to increase by 10%, this would increase the obligation by approximately ~~$201,538~~$2,926 as of ~~June 30, 2021.~~March 31, 2022. If the volatility were to decrease by 10%, this would decrease the obligation by approximately ~~$192,930~~$1,348 as of ~~June 30, 2021.~~March 31, 2022.

~~Table of Contents~~

The following table is a continuity schedule of changes to the Company’s derivative liabilities:


	Total		Total

Balance, September 30, 2019	$	16,520
Change in fair value		110,856

Balance, September 30, 2020	$	127,376	$	127,376
Change in fair value		470,132		(107,023)

Balance, June 30, 2021	$	597,508
Balance, September 30, 2021			$	20,353
Change in fair value				(18,424)

Balance, March 31, 2022			$	1,929

Derivatives with expected life of less than one year	$	0	$	1,929
Derivatives with expected life greater than one year	$	597,508	$	0

~~10.~~9. SHAREHOLDERS’ EQUITY

Authorized

Unlimited common shares, without par value.

Unlimited preferred shares, without par value.

February 2021 Financing

On February 22, 2021, the Company completed an underwritten public offering for aggregate gross proceeds of $149,999,985 (the “February 2021 Financing”). The Company issued a total of 5,555,555 common shares of the Company at a public offering price of $27.00 per share, which includes the underwriters having exercised their 30-day option to purchase an additional 724,637 common shares. In connection with the February 2021 Financing, the Company paid cash commissions of $8,999,999 and incurred other transaction costs of $229,451.

~~July 2020 Financing~~

~~On July 31, 2020, the Company completed an underwritten public offering for aggregate gross proceeds of $48,990,000 (the “~~~~July 2020 Financing~~~~”). The Company issued a total of 7,100,000 common shares of the Company at a public offering price of $6.00 per share. Additionally, the underwriters exercised a~~ ~~30-day~~ option to purchase up to an additional 1,065,000 common shares. In connection with the July 2020 Financing, the Company paid cash commissions of $2,939,400 and incurred other transaction costs of $212,256.

~~August 2019 Financing~~

~~On August 27, 2019, the Company closed a public offering of equity securities of the Company in Canada and a concurrent private placement of equity securities in the United States (the “~~~~August 2019 Financing~~”). The Company issued a total of 6,080,596 common shares and 11,919,404 pre-funded warrants in lieu of common shares of the Company at a price of $2.00 per security for aggregate gross proceeds of $36,000,000. Each pre-funded warrant entitles the holder thereof to acquire 1 common share at a nominal exercise price for a period of five years. In connection with the August 2019 Financing, the Company paid cash commissions of $1,978,770 and incurred other transaction costs of $698,162.

~~Table of Contents~~

Nomination Rights

In connection with a January 2016 private placement of 227,273 Units, a Unit consisting of 1 common share, 1 7-year warrant and one-half of one 2-year warrant, of the Company, Clarus Lifesciences III, L.P. (“Clarus”) acquired 106,061 common shares. Clarus is entitled to nominate two directors to the board of directors of the Company, one of which must be an independent director and preapproved by the Company. These nomination rights will continue for so long as Clarus holds greater than or equal to 53,030 common shares, subject to adjustment in certain circumstances.

Table of Contents

~~Equity~~Omnibus incentive plans

~~Restricted share units plan~~

The Company has adopted ~~a Restricted Share Unit Plan~~an omnibus incentive plan (“~~RSU~~Omnibus Plan”) consistent with the policies and rules of the Nasdaq. Pursuant to the ~~RSU~~Omnibus Plan, ~~RSUs~~the Company may ~~be granted with vesting criteria~~issue stock options, share appreciation rights, restricted shares, restricted share units and ~~periods are approved by~~other share-based awards. As of March 31, 2022, the ~~Board of Directors at its discretion. The RSUs~~Company has not issued any instruments other than stock options under the ~~RSU Plan may be accounted for as either equity-settled or cash-settled share-based payments. At June 30, 2021, there are 0 RSUs outstanding.~~Omnibus Plan.

As of ~~June 30, 2021~~March 31, 2022, the ~~Stock Option~~Omnibus Plan ~~and RSU Plan have~~has a ~~combined~~ maximum of ~~7,342,788~~8,410,907 common shares which may be reserved for issuance.

Employee Share Purchase Plan

The Company has adopted an Employee Share Purchase Plan (“ESPP”) under which qualifying employees may be granted purchase rights (“Purchase Rights”) to the Company’s common shares at not less of 85% of the market price at the lesser of the date the Purchase Right is granted or exercisable. The Company currently holds offerings consisting of ~~nine-month~~six-month periods commencing on January 1 and July 1 and ending on June 30 and December 31 of each calendar year. As of ~~June 30, 2021,~~March 31, 2022, the ESPP has a maximum of ~~252,418 (2020~~249,974 (September 30, 2021 – ~~284,887)~~252,418) common shares reserved for issuance.

Eligible employees are able to contribute up to 15% of their gross base earnings for purchases under the ESPP through regular payroll deductions. Purchase of shares under the ESPP are limited for each employee at $25,000 worth of the Company’s common shares (determined using the lesser of (i) the market price of a common share on the first day of an applicable purchase period and (ii) the market price of a common share on the purchase date) for each calendar year in which a purchase right is outstanding.

During the ~~nine~~six months ended ~~June 30, 2021,~~March 31, 2022, the Company issued ~~10,702~~2,444 shares ~~(2020~~(2021 – ~~16,506)~~5,261) upon the exercise of Purchase Rights. The Company recognizes compensation expense for purchase rights on a straight-line basis over the service period.


	For the three months				For the nine months				For the three months ended				For the six months ended
	ended June 30,				ended June 30,				March 31,				March 31,
	2021			2020	2021			2020	2022			2021	2022			2021

Research and development expense	$	9,123	$	19,414	$	23,816	$	24,984	$	8,483	$	9,123	$	12,133	$	14,693
General and administrative		17,381		45,467		35,327		46,033		805		17,381		6,957		17,946
	$	26,504	$	64,881	$	59,143	$	71,017	$	9,288	$	26,504	$	19,090	$	32,639

The Company measures the purchase rights based on their estimated grant date fair value using the Black-Scholes option pricing model and the estimated number of shares that can be purchased. The following weighted average assumptions were used for the valuation of purchase rights:


	2022		2021

Risk-free interest rate	0.44	%	0.19	%
Expected life of share purchase rights	6 months		6 months
Expected annualized volatility	87.90	%	61.26	%
Dividend	0		0

Stock options

Pursuant to the Omnibus Plan, options may be granted with expiry terms of up to 10 years, and vesting criteria and periods are approved by the Board of Directors at its discretion. The options issued under the Stock Option Plan are accounted for as equity-settled share-based payments.

Table of Contents

2021

2020


Risk-free interest rate

0.19
%
1.70
%
Expected life of share purchase rights

6 months

6 months

Expected annualized volatility

61.26
%
95.68
%
Dividend

0

0

~~Stock options~~

The Company has adopted a Stock Option Plan consistent with the policies and rules of the Nasdaq. Pursuant to the Stock Option Plan, options may be granted with expiry terms of up to 10 years, and vesting criteria and periods are approved by the Board of Directors at its discretion. The options issued under the Stock Option Plan are accounted for as equity-settled share-based payments.

Stock option transactions are summarized as follows:


		Weighted			Weighted
	Number	Average		Number	Average
	of Options	Exercise Price*		of Options	Exercise Price*

Balance, September 30, 2019	1,122,461	$	4.59
Options granted	4,218,000		3.31
Options exercised	(416)		(2.20)
Options expired/forfeited	(30,461)		(28.46)

Balance, September 30, 2020	5,309,584	$	3.42	5,309,584	$	3.42
Options granted	1,889,646		9.87	1,889,646		9.87
Options exercised	(323,610)		(3.67)	(323,610)		(3.68)
Options expired/forfeited	(72,390)		(4.46)	(72,390)		(4.46)

Balance outstanding, June 30, 2021	6,803,230	$	5.20
Balance exercisable, June 30, 2021	2,496,961	$	3.50
Balance, September 30, 2021				6,803,230	$	5.20
Options granted				170,000		8.85
Options exercised				(72,910)		(4.41)
Options expired/forfeited				(104,584)		(3.18)

Balance outstanding, March 31, 2022				6,795,736	$	5.33
Balance exercisable, March 31, 2022				3,908,576	$	4.14

*	Options exercisable in Canadian dollars as of ~~June 30, 2021~~March 31, 2022 are translated at current rates to reflect the current weighted average exercise price in US dollars for all outstanding options.

At March 31, 2022, options were outstanding enabling holders to acquire common shares as follows:


			Weighted average remaining
	Exercise price	Number of options	contractual life (years)

$	3.23	3,674,188	7.52	*
$	3.59	26,667	7.55
$	3.81	185,816	6.87
$	4.00	539,518	5.73
$	4.67	183,511	7.59
$	7.00	1,491,646	8.70
$	8.47	120,000	9.54
$	9.76	50,000	9.89
$	13.96	190,000	8.79
$	29.63	100,000	9.08
$	31.62	75,000	9.17
C$	4.90	129,503	5.16
C$	5.06	29,887	6.87	*
		6,795,736	7.71

*25,258 options expired unexercised subsequent to March 31, 2022

Share-based compensation

During the six months ended March 31, 2022, the Company granted a total of 170,000 (2021 – 1,714,646) stock options with a weighted average fair value of $8.85 per option (2021 – $7.77).

Table of Contents

~~At June 30, 2021, options were outstanding enabling holders to acquire common shares as follows:~~

Weighted average remaining

Exercise price

Number of options

contractual life (years)

$
2.20

4,584

7.95

$
3.23

3,794,603

8.27

$
3.59

26,667

8.30

$
3.81

185,816

7.62

$
4.00

539,518

6.48

$
4.67

183,511

8.34

$
7.00

1,508,146

9.45

$
13.96

190,000

9.54

$
29.63

100,000

9.83

$
31.62

75,000

9.92

C$
4.90

163,154

6.06

C$
5.06

32,231

7.62

6,803,230

8.40

~~Share-based compensation~~

~~During the nine months ended June 30, 2021, the Company granted a total of 1,889,646 (2020 – 4,218,000) stock options with a weighted average fair value of $9.87 per option (2020 – $3.31).~~

The Company recognized share-based payments expense for options granted and vesting, net of recoveries on cancellations of unvested options, during the ~~three months~~period ended ~~June 30,~~March 31, 2022 and 2021 ~~and 2020~~ with allocations to its functional expense as follows:


	For the three months				For the nine months				For the three months ended				For the six months ended
	ended June 30,				ended June 30,				March 31,				March 31,
	2021			2020	2021			2020	2022			2021	2022			2021

Research and development expense	$	1,234,669	$	363,527	$	2,299,369	$	1,539,851	$	1,113,376	$	782,846	$	2,369,077	$	1,064,700
General and administrative		1,522,769		1,080,540		4,294,101		4,736,318		740,689		1,854,336		1,975,277		2,771,332
									$	1,854,065	$	2,637,182	$	4,344,354	$	3,836,032
	$	2,757,438	$	1,444,067	$	6,593,470	$	6,276,169

The following weighted average assumptions were used for the Black-Scholes option-pricing model valuation of stock options granted:




	2021			2020		2022		2021

Risk-free interest rate		0.44	%	1.54	%	1.20	%	0.39	%
Expected life of options		10.00	years	10.00	years	10.00	years	10.00	years
Expected annualized volatility		78.16	%	77.00	%	80.00	%	78.05	%
Dividend		0		0		0		0

~~Table of Contents~~

Warrants

Warrant transactions are summarized as follows:


		Weighted			Weighted
	Number	Average		Number	Average
	of Warrants	Exercise Price		of Warrants	Exercise Price

Balance, September 30, 2019	12,393,092	$	1.31
Warrants exercised	(3,120,115)		(0.08)

Balance, September 30, 2020	9,272,977	$	1.73	9,272,977	$	1.73
Warrants exercised	(3,913,227)		(0.10)	(6,038,227)		(0.06)

Balance outstanding and exercisable, June 30, 2021	5,359,750	$	2.92
Balance outstanding and exercisable, September 30, 2021 and March 31, 2022				3,234,750	$	4.84

At ~~June 30, 2021,~~March 31, 2022, warrants were outstanding enabling holders to acquire common shares as follows:


Number
of Warrants		Exercise Price		Expiry Date		Exercise Price		Expiry Date

227,273	⁽¹⁾	US$	66.00	January 14, 2023	⁽¹⁾	US$	66.00	January 14, 2023
7,477		US$	42.80	November 18, 2023		US$	42.80	November 18, 2023
80,000		US$	4.00	January 9, 2023		US$	4.00	January 9, 2023
5,045,000	⁽²⁾	US$	0.0001	August 23, 2024
5,359,750
2,920,000						US$	0.0001	August 23, 2024
3,234,750

(1)	Detailed terms of the 2016 Warrants are included in Note 9.

~~(2)~~

~~2,125,000 prefunded warrants exercised subsequent to June 30, 2021. (Note 14)~~8.

Table of Contents

~~11.~~10. RELATED PARTY TRANSACTIONS

Included in accounts payable and accrued liabilities at ~~June~~March 31, 2022 is $77,658 (September 30, 2021 ~~is $76,535 (September 30, 2020~~ - ~~$87,846)~~$82,036) due to related parties with respect to key management personnel compensation and expense reimbursements. Amounts due to related parties are non-interest bearing, with no fixed terms of repayment.

~~12.~~11. SEGMENTED INFORMATION

The Company works in 1 industry being the development of small molecule drugs for prostate cancer. The Company’s right of use asset is located in the USA.

~~13.~~12. FINANCIAL INSTRUMENTS AND RISK

The Company’s financial instruments consist of cash and cash equivalents, short-term investments, receivables, accounts payable and accrued liabilities and derivative liabilities. The fair value of cash and cash equivalents, GICs and term deposists included in short-term investments, receivables and accounts payable and accrued liabilities approximates their carrying values due to their short term to maturity. The fair value of U.S. treasury securities, corporate debt securities and commercial paper included in short-term investments are measured using Level 2 inputs based on standard observable inputs, including reported trades, broker/dealer quotes, and bids and/or offers (Note 4).The derivative liabilities are measured using ~~level~~Level 3 inputs (Note 9)8).

~~Table of Contents~~

Fair value estimates of financial instruments are made at a specific point in time, based on relevant information about financial markets and specific financial instruments. As these estimates are subjective in nature, involving uncertainties and matters of judgement, they cannot be determined with precision. Changes in assumptions can significantly affect estimated fair values.

Financial risk factors

The Company’s risk exposures and the impact on the Company’s financial instruments are summarized below:

Credit risk

Financial instruments that potentially subject the Company to a significant concentration of credit risk consist primarily of cash and cash equivalents, short-term investments and receivables. The ~~Company’s receivables are mainly the balance remaining on the CPRIT Grant. The~~ Company limits its exposure to credit loss by placing its cash with major financial institutions. The Company considers highly liquid investments with a maturity of up to twelve months when purchased to be short-term investments. Short-term investments includes investments that may have maturity dates exceeding one year at the date of purchase; however, the Company may liquidate investment positions prior to maturity to implement management strategies. The Company maintains an investment policy which requires certain minimum investment grades over its investment instruments.

As of ~~June 30, 2021,~~March 31, 2022, cash and cash equivalents consisted of cash in Canada and the United States and term deposits in ~~Canada.~~Canada and investments in certain instruments which have a maturity of less than three months at the date of purchase. Balances in cash accounts exceed amounts insured by the Canada Deposit Insurance Corporation for up to C$100,000 and by the Federal Deposit Insurance Corporation for up to $250,000. Amounts due from government agencies are considered to have minimal credit risk.

Liquidity risk

The Company’s approach to managing liquidity risk is to ensure that it will have sufficient liquidity to meet liabilities when due. As of ~~June 30, 2021,~~March 31, 2022, the Company had working capital of ~~$199,949,211.~~$178,353,354. The Company does not generate revenue and will be reliant on external financing to fund operations. Debt and equity financing are dependent on market conditions and may not be available on favorable terms.

Table of Contents

Market risk

Market risk is the risk of loss that may arise from changes in market factors such as interest rates, and foreign exchange rates.

(a)Interest rate risk

As of ~~June 30, 2021,~~March 31, 2022, the Company has cash and cash equivalents balances and ~~GICs~~short-term investments which are interest bearing. Interest income is not central to the Company’s capital management strategy and not significant to the Company’s projected operational ~~budget and related interest~~budget. Interest rate fluctuations are not significant to the Company’s risk assessment.

(b)Foreign currency risk

The Company’s foreign currency risk exposure relates to net monetary assets denominated in Canadian ~~dollars.~~dollars, UK pound and Euro. The Company maintains its cash and cash equivalents in US dollars and converts on an as needed basis to discharge Canadian denominated expenditures. A 10% change in the foreign exchange rate between the Canadian dollar, UK Pound, Euro and U.S. dollar in relation to Canadian dollar, UK Pound, Euro dollars held at ~~June 30, 2021~~March 31, 2022 would result in a fluctuation of ~~$28,741~~$6,565 in the net loss recognized for the period. The Company does not currently engage in hedging activities.

~~14. SUBSEQUENT EVENT~~

~~On August 9, 2021, the Company issued 2,125,000 common shares upon exercise of 2,125,000 prefunded warrants.~~

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operation

The following discussion should be read in conjunction with the attached financial statements and notes thereto. This Quarterly Report on Form 10-Q, including the following sections, contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those expressed or implied by such forward-looking statements. For a detailed discussion of these risks and uncertainties, see “Risk Factors” in our Annual Report on Form 10-K. We caution the reader not to place undue reliance on these forward-looking statements, which reflect management’s analysis only as of the date of this Quarterly Report on Form 10-Q. We undertake no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this Quarterly Report on Form 10-Q. Throughout this discussion, unless the context specifies or implies otherwise, the terms “ESSA,” “the Company,” “we,” “us,” and “our” refer to ESSA Pharma Inc. and its subsidiaries. For a discussion regarding our financial condition and results of operations for fiscal ~~2020~~2021 as compared to fiscal ~~2019~~2020 see Item 7 of our Annual Report on Form 10-K for the fiscal year ended September 30, ~~2020,~~2021, filed with the SEC on ~~December 15, 2020.~~November 18, 2021.

Overview

ESSA is a clinical stage pharmaceutical company, focused on developing novel and proprietary therapies for the treatment of prostate cancer with an initial focus on patients whose disease is progressing despite treatment with current standard of care therapies, including second-generation antiandrogen drugs such as abiraterone, enzalutamide, apalutamide, and darolutamide. The Company believes its latest series of investigational compounds, including its product candidate EPI-7386, have the potential to significantly expand the interval of time in which patients with castration-resistant prostate cancer (“CRPC”) can benefit from anti-hormone-based therapies. Specifically, the compounds are designed to disrupt the androgen receptor (“AR”) signaling pathway, the primary pathway that drives prostate cancer growth and prevent AR activation through selective binding to the N-terminal domain (“NTD”) of the AR. In this respect, the Company’s compounds are designed to mechanistically differ from classical non-steroid antiandrogens. These antiandrogens interfere either with androgen synthesis (i.e., abiraterone), or with the binding of androgens to the ligand-binding domain (“LBD”), located at the opposite end of the receptor from the NTD (i.e., “lutamides”). A functional NTD is essential for ~~activation~~the functionality of the AR; blocking the NTD inhibits AR-driven transcription and therefore androgen-driven biology.

The Company believes that the transcription inhibition mechanism of its preclinical compounds is unique and has the potential advantage of bypassing several of the identified mechanisms of resistance to the antiandrogens currently used in the treatment of CRPC. The Company has been granted by the United States Adopted Names ("USAN") Council a unique USAN stem "-aniten" to recognize this new first-in-class mechanistic class. The Company refers to this series of proprietary investigational compounds as the ~~“Aniten”~~“aniten” series. In preclinical studies, blocking the NTD has demonstrated the capability to prevent AR-driven gene expression. A previously completed Phase I clinical trial of ESSA’s first-generation agent, ralaniten acetate (“~~EPI-506”~~EPI-506”) administered to patients with metastatic CRPC (“mCRPC”) refractory to current standard of care therapies demonstrated prostate-specific antigen (“PSA”) declines, a sign of inhibition of AR-driven biology. This inhibition, however, was neither deep nor sustained enough to confer clinical benefit and the Company made the decision to develop a more potent next generation drug which would also have a longer half-life. The Company has done so and is now in clinical trial with this next generation ~~Aniten,~~aniten, EPI-7386.

Table of Contents

According to the American Cancer Society, in the United States, prostate cancer is the second most frequently diagnosed cancer among men, behind skin cancer. Approximately one-third of all prostate cancer patients who have been treated for local disease with curative intent will subsequently have rising serum levels of PSA, which is an indication of recurrent disease with or ~~advanced disease.~~without development of distant metastasis. Patients with ~~advanced~~recurrent disease ~~often~~as indicated by rising PSA usually undergo initial androgen ablation therapy using analogues of luteinizing hormone releasing hormone or surgical castration; this approach is termed “androgen deprivation therapy” (“ADT”). Most ~~advanced prostate cancer~~of these patients initially respond to this androgen ablation therapy; however, many experience a recurrence in tumor growth despite the reduction of testosterone to castrate levels, and at that point are considered to have CRPC. Following diagnosis of CRPC, patients have been generally treated with antiandrogens that block the binding of androgens (darolutamide, enzalutamide, apalutamide or bicalutamide) to the AR, or inhibit synthesis of androgens (abiraterone). More recently, significant improvements in ~~progression-free~~progression free survival and overall survival have been achieved by utilizing this latest generation of antiandrogens in combination with ADT earlier in the disease natural history ~~in newly diagnosed metastatic prostate cancer.~~(i.e., HSPC and nmCRPC).

Since the ~~mid-20~~^thmid-20th century, it has been recognized that the growth of prostate tumors is in large part mediated by an activated AR. Generally, there are three means of activating the AR. First, androgens such as dihydrotestosterone can activate AR by binding to its LBD. Second, CRPC can be driven by variants of AR that lack an LBD, are constitutively activated, and consequently do not require androgen for activation. A third mechanism, of less certain clinical significance, may involve certain signaling pathways that activate AR independent of androgen activity. Generally, current drugs for the treatment of prostate cancer are directed against the first mechanism by either (i) interfering with the production of androgen, or (ii) preventing androgen from binding to the LBD. Over time, these approaches eventually fail due to mechanisms of resistance which ~~all~~ involve the LBD end of the receptor, whether at the DNA (AR amplification or LBD mutations) or RNA level (emergence of AR splice variants). With respect to the development of alternative pathway mechanisms of AR activation, tumors might also be insensitive to anti-androgen activity. Finally, in patients who have been treated for years with various anti-androgen therapies, genomic changes may lead to additional, non-AR-related oncogenic drivers, also insensitive to inhibition of AR biology.

The Company believes that through their potential to block androgen-driven gene transcription by using a unique mechanism involving the NTD and thereby bypassing these known mechanisms of resistance to current antiandrogens, the ~~Aniten~~aniten series of compounds hold the potential to be effective in cases where ~~current therapies have failed.~~LBD-based mechanisms of resistance to second generation antiandrogens in otherwise AR-driven disease are operating. The results from both extensive preclinical studies and the initial clinical experience support the Company’s belief. In preclinical studies, the ~~Aniten~~aniten series of compounds has been observed to shrink AR-dependent prostate cancer xenografts, including tumors both sensitive and resistant to the second-generation antiandrogens such as enzalutamide. Plasma PSA level declines were observed in the initial results of the Phase I study of EPI-7386 as described below. Importantly with respect to the potential clinical application of NTD inhibition, recent studies by the Company and its collaborators have also suggested the potential advantage for combinations of the Company’s ~~Aniten~~aniten compounds with currently approved antiandrogens to inhibit AR-driven biology more completely than AR inhibition from either end of the receptor alone. This hypothesis is supported by the clinical trial results obtained in recent years of the superior overall survival obtained with initial combination therapy with ADT and latest generation anti-androgens relative to the administration of these two therapies sequentially.

Table of Contents

The Phase I clinical trial of the first generation ~~Aniten~~aniten EPI-506 provided evidence regarding the safety and tolerability for the potential mechanism of transcription inhibition of AR-driven biology. Patients generally tolerated doses of ~~EPI-506~~EPI-506 at overall exposures consistent with those associated with therapeutic activity in animal models. Possible proof of concept was observed with short duration PSA declines of up to 37% being observed in some patients whose disease was highly refractory to second-generation antiandrogen treatment. However, this first-generation drug demonstrated poor pharmaceutical properties. The drug was rapidly metabolized in humans, leading to a very short half-life of circulating drug and suboptimal drug exposures. Consequently, very high doses were required to achieve modest drug exposures, with the relatively short half-life limiting the therapeutic exposure of the drug within a 24-hour period. This limitation, together with other demonstrated unfavorable pharmaceutical properties, led to the Company’s decision to discontinue EPI-506 development in favor of focusing on the development of a next generation of ~~Anitens.~~anitens. This next generation includes significantly more potent drugs designed also to exhibit increased resistance to metabolism and therefore a longer predicted circulating half-life. The Company’s lead product candidate EPI-7386 has demonstrated these and other favorable characteristics in extensive preclinical characterization studies which the Company has presented in a series of poster presentations at scientific meetings over the last ~~year.~~two years.

~~Table of Contents~~

While the potential importance of the NTD as a drug target has been appreciated for more than two decades, for technical reasons this has been a difficult target for therapeutic agent development. The NTD of the AR is flexible with a high degree of intrinsic disorder making it difficult for use in classic crystal structure-based drug design. The Company is not currently aware of any ~~success~~clinical-stage NTD AR inhibitors that are in development by other drug development ~~companies in developing drugs that bind specifically to this drug target.~~companies. The nature of the highly specific binding of the ~~Aniten~~aniten compounds to the NTD, and the biological consequences of that binding, have been defined in recent scientific studies. The selectivity of the binding, based on in vivo imaging as well as in vitro studies, has been consistent with the favorable toxicological results observed in preclinical studies of the first-generation EPI-506 and the subsequent safety results observed in the Phase I trial of ~~EPI-506.~~EPI-506. The Company ~~is currently conducting, together with external academic and industry collaborators, extensive~~has completed a series of biophysical and biological studies ~~to reveal more precisely~~revealing the ~~nature~~interaction and binding of EPI-7386 ~~binding,~~to the NTD of the AR and ~~the specific consequent effects on prostate cancer biology.~~presented these findings at several medical conferences in 2021.

The incidence of both metastatic and non-metastatic CRPC continues to rise, and using a dynamic progression model, Scher et alal.¹ projected a 2020 incidence of 546,955 and prevalence of 3,072,480. The Company believes that the ~~Aniten~~aniten series of compounds could ultimately hold potential benefit for many of those patients. In its early clinical development, the Company intends to initially focus on patients who have failed second-generation antiandrogen therapies (i.e., abiraterone and/or lutamides) for the following reasons:

●

CRPC treatment remains a prostate cancer market segment with an apparent and significant unmet therapeutic need and is therefore a potentially large market;

●

the Company believes that the unique mechanism of action of its ~~Aniten~~aniten compounds is well suited to treat those patients who have failed AR LBD focused therapies and whose biological characterization reveals that their tumors are still largely driven by AR biology; and

●

the Company expects that the relatively large number of patients with an apparent unmet therapeutic need in this area will facilitate timely enrollment in its clinical trials.

¹ Scher HI, Solo K, Valant J, Todd MB, Mehra M (2015) Prevalence of Prostate Cancer Clinical States and Mortality in the United States: Estimates Using a Dynamic Progression Model. PLoS ONE 10(10): e0139440. doi:10.1371/journal.pone.013944

Table of Contents

Furthermore, the Company believes that a successful Phase I clinical trial will facilitate the early study of the combination of EPI-7386 with second-generation antiandrogens. The Company and its collaborators have developed preclinical in vitro and in vivo evidence supporting further evaluation of the combination of NTD inhibitors together with the LBD inhibiting antiandrogens. The Company believes that the application of two independent, complementary mechanisms of AR transcription inhibition may result in greater suppression of androgen activity and the delay or prevention of drug resistance. Recent progress in the clinical treatment of prostate cancer has resulted from the earlier utilization of antiandrogens in combination with classic ADT, consistent with the premise that more effective androgen suppression may yield clinical benefit. The Company believes that the introduction of NTD inhibitors such as EPI-7386 therefore has potential to improve androgen suppression, delay the emergence of resistance, and result in improved clinical benefit. The Company has announced a number of collaborative studies in line with this strategy. The first collaboration, with Janssen Research & Development, LLC (“Janssen”), to study in clinical trials the safety and potential benefit of combination of EPI-7386 with abiraterone acetate with prednisone as well as the combination of EPI-7386 with apalutamide was announced January 13, 2021. A second collaboration and supply agreement with Astellas Pharma Inc. (“Astellas”) to evaluate EPI-7386 in combination with Astellas and Pfizer Inc.’s androgen receptor inhibitor, enzalutamide, in patients with ~~metastatic castration-resistant prostate cancer (“mCRPC”)~~mCRPC was announced on February 24, 2021. A third collaboration and supply agreement with Bayer Consumer Care AG (“Bayer”) to evaluate EPI-7386 in combination with Bayer’s androgen receptor inhibitor, darolutamide, in patients with mCRPC was announced on April 28, 2021.

The Company is party to a license agreement with the British Columbia Cancer Agency and the University of British Columbia dated December 22, 2010, as amended on February 10, 2011, ~~and on~~ May 27, 2014, and May 25, 2021 (the “License Agreement”), which provides the Company with exclusive world-wide rights to the issued patents and patent applications related to the EPI-002 ~~compound,~~and the ~~active compound of the previous clinical candidate EPI-506.~~EPI-7386 compounds.

~~Table of Contents~~

The Company believes that it has developed a strong and defensive intellectual property position for ~~multiple EPI~~aniten structural classes. As of March 2022, ESSA owns rights to 48 issued patents, including 13 issued U.S. patents, that are in force and ~~Aniten structural classes, with 16 pending and maintained patent families which~~ cover multiple EPI- and ~~Aniten~~aniten structural classes of compounds with different structural motifs/analogues. As of March 2022, 5 of these issued patents cover the EPI-7386 compound and are expected to provide protection until 2036 to 2041. Patent applications are also pending in the United States and in contracting states to the Patent Cooperation Treaty for the ~~Aniten~~aniten next-generation NTD inhibitors, with ~~expiry~~expected expiration dates between ~~2036-2040.~~2036-2041.

Completed Phase I Clinical Study of EPI-506

The Company conducted an initial proof-of-concept Phase I clinical study utilizing the first-generation ~~Aniten~~aniten compound, EPI-506. The objective of the EPI-506 Phase I clinical trial was to explore the safety, tolerability, maximum tolerated dose and pharmacokinetics of EPI-506, in addition to anti-tumor activity in asymptomatic or minimally symptomatic patients with mCRPC who were no longer responding to either abiraterone or enzalutamide treatments, or both. Efficacy endpoints, such as PSA reduction, and other disease progression criteria were evaluated. Details relating to the design of the Phase I/II clinical trial of EPI-506 are available on the U.S. National Institutes of Health clinical trials website (see https://clinicaltrials.gov).

The Investigational New Drug (“IND”) application to the FDA for EPI-506, to begin a Phase I clinical trial, was allowed in September 2015, with the first clinical patient enrolled in November 2015. The Company’s Clinical Trial Application (“CTA”) submission to Health Canada was subsequently also cleared. Based on allometric scaling, an initial dose level of EPI-506 of 80 mg was determined. However, following the enrollment of the initial cohorts, it became apparent that EPI-506 exposure was much lower in humans than projected. EPI-506 dosing was escalated aggressively to allow patients in the clinical study greater exposure to the drug. The highest dose patients ultimately received was 3600 mg of EPI-506, administered in a single dose or split into two doses daily. The initial data from the Phase I clinical trial was presented at the European Society of Medical Oncology meeting in September 2017.

Table of Contents

Conducted at five sites in the United States and Canada, the open-label, single-arm, dose-escalation study evaluated the safety, pharmacokinetics, maximum-tolerated dose and anti-tumor activity of EPI-506 in men with end-stage mCRPC who had progressed after prior enzalutamide and/or abiraterone treatment and who may have received one prior line of chemotherapy. Twenty-eight patients were available for analysis, with each patient having received four or more prior therapies for prostate cancer at the time of study entry. Patients self-administered oral doses of EPI-506 ranging from 80 mg to 3600 mg, with a mean drug exposure of 85 days (range of eight to 535 days). Four patients underwent prolonged treatment (with a median of 318 days; and a range of 219 to 535 days at data cut-off), following intra-patient dose escalation. PSA declines, a measure of potential efficacy, ranging from 4% to 37% were observed in five patients, which occurred predominantly in the higher dose cohorts (≥1280 mg).

EPI-506 was generally well-tolerated with favorable safety results observed across all doses up to 2400 mg. At a dose of 3600 mg, gastrointestinal adverse events (nausea, vomiting and abdominal pain) were observed in two patients: one patient in the once-daily (“QD”) dosing cohort and one patient in the 1800 mg twice-daily dosing cohort, leading to study discontinuation and a dose-limiting toxicity (“DLT”) due to more than 25% of doses being missed in the 28-day safety reporting period. A separate patient in the 3600 mg QD cohort experienced a transient Grade 3 increase in liver enzymes (AST/ALT), which also constituted a DLT, and enrollment was consequently concluded in this cohort.

Although the Company believes that the safety results and possible signs of anti-tumor activity observed at higher dose levels support the concept that inhibiting the AR-NTD may provide a clinical benefit to mCRPC patients, the pharmacokinetic and metabolic studies revealed the limitations of the first generation agent EPI-506. Through its discovery research the Company had concluded that it should be feasible to develop a next generation of NTD inhibitor which would demonstrate greater potency, reduced metabolism and other improved pharmaceutical properties. As a result, the Company announced on September 11, 2017 its decision to discontinue the further clinical development of EPI-506 and to implement a corporate restructuring plan to focus research and development resources on its next-generation ~~Anitens~~anitens targeting the AR-NTD. The restructuring included a decrease in headcount and a reduction of operational expenditures related to the clinical program.

~~Table of Contents~~

Phase I Clinical Study of EPI-7386

The Company’s family of next-generation investigational ~~Aniten~~aniten compounds incorporate multiple chemical scaffold changes to the first-generation drugs which in preclinical studies retain NTD inhibition of the AR. In addition, they have shown improvement in a range of attributes when compared to the first-generation compound, EPI-506, in preclinical studies. In in vitro assays measuring inhibition of AR transcriptional activity, these product candidates demonstrated 20 times higher potency than EPI-506 or its active metabolite, EPI-002. In addition, the compounds have demonstrated increased metabolic stability in preclinical studies, suggesting the potential for longer half-lives in humans. Lastly, the compounds have demonstrated more favorable pharmaceutical properties relative to EPI-506. The Company believes that these product candidates, if successfully developed and approved, may offer advancements in ease and cost of large-scale manufacture, drug product stability, and suitability for commercialization globally. From this series of next-generation compounds, EPI-7386 was selected as the lead candidate for clinical development and an IND was submitted to the FDA on March 30, 2020 and was allowed by the FDA on April 30, 2020. A CTA was filed with Health Canada in April 2020 and clearance was subsequently received. The Phase I clinical trial of EPI-7386 “Oral EPI-7386 in Patients With Metastatic Castration-Resistant Prostate Cancer (EPI-7386)” was started in June 2020 with the first patient dosed in July 2020 and is currently actively enrolling patients (www.clinicaltrials.gov). ~~A poster presentation of~~In September 2021 the ~~initial pharmacokinetic, safety and tolerability experience~~Company filed a protocol amendment with the ~~200 mg cohort was~~FDA to focus further monotherapy development in less heavily pretreated patients with mCRPC. The Company has presented aspreclinical and clinical scientific data relative to EPI-7386 in a number of poster presentations at scientific meetings in the ~~ASCO-GU meeting in February~~past year.

Table of 2021. Subsequently, at the 2021 American Association of Cancer Research (AACR) Annual Meeting, which took place virtually April 10-15, 2021, ESSA presented an e-poster which further described the in vitro characterization of the mechanism of action of EPI-7386.Contents

Our Strategy

The Company’s initial therapeutic goal is to develop a safe and effective therapy for prostate cancer patients whose tumors have progressed on current antiandrogen ~~therapy.~~therapy while remaining prevalently driven by the AR pathway. However, preclinical studies suggest the potential of the Company’s ~~Aniten~~aniten compounds to increase therapeutic activity when combined with antiandrogens at the earlier stage of the disease. Therefore, while the Company’s ~~first~~initial priority is to continue Phase I clinical development of EPI 7386 as a single agent, in parallel the Company has also been conducting preclinical studies ~~and planning clinical studies to evaluate EPI-7386 in combination with other agents. These preclinical studies are being conducted~~ in collaboration with industry ~~collaborators~~ and academic institutions. In addition, the Company has ~~engaged in discussions~~developed collaborations with the relevant pharmaceutical companies in the prostate cancer space ~~regarding potential collaborative~~for the conduct of clinical trials of combination ~~therapy~~therapies in earlier line of treatment for patients with ~~mCRPC, including those announced~~mCRPC. The Company’s intent to support these collaborative clinical trials with Janssen, Astellas, and Bayer have been announced. The first of these studies, involving the combination of EPI-7386 with enzalutamide, is being conducted in collaboration with Astellas and Pfizer. ESSA is operationally conducting this trial, with an initial Phase I dose equilibration Phase following by a randomized Phase 2 trial involving a planned 120 patients. The enzalutamide for this trial will be supplied by Astellas. The first patient in this Phase 1/2 study was dosed in January 2022. The combination trials with abiraterone acetate with prednisone, and with apalutamide that are being conducted by Janssen, have been initiated. The Bayer-led Phase 1/2 trial will evaluate EPI-7386 in combination with darolutamide in earlier line MCRPC patients. ESSA will provide EPI-7386 for the combination trials being conducted by Janssen and Bayer. ~~In future~~From the preclinical ~~studies,~~perspective, the Company ~~intends to~~together with collaborators is further ~~explore~~exploring other potential applications for AR-NTD inhibitors, including breast cancer and other AR-associated cancers.

The identification and characteristics of the IND candidate EPI-7386

The purpose of the next-generation program has been to identify drug candidates with increased potency, reduced metabolic susceptibility and superior pharmaceutical properties compared to ESSA’s first-generation compounds. Structure-activity relation studies conducted on the chemical scaffold of ESSA’s first-generation compounds have resulted in the generation of a new series of compounds that have demonstrated higher potency and predicted longer half-lives. Multiple changes in the chemical scaffold have also been incorporated with the goal of improving ADME (absorption, distribution, metabolism, and excretion) and pharmaceutical properties of the chemical class.

Several next-generation aniten molecules met prespecified preclinical target product profile goals regarding potency, stability, selectivity and pharmaceutical properties. On March 26, 2019, the Company announced the nomination of EPI-7386 as its lead clinical candidate for the treatment of mCRPC through inhibition of the NTD of the androgen receptor. In preclinical studies, EPI-7386 has displayed activity in vitro in numerous AR-dependent prostate cancer models including models where second-generation antiandrogens are inactive. In addition, EPI-7386 is significantly more potent, metabolically stable and more effective in preclinical studies compared to ESSA’s first-generation compound, EPI-506. Lastly, EPI-7386 has demonstrated a favorable tolerability profile in all animal studies of the compound conducted to date.

~~Table of Contents~~

Following IND-enabling studies, ESSA filed an IND for EPI-7386 in mCRPC at the end of the first calendar quarter of 2020, and following the receipt of clearance by the FDA and allowance by Health Canada, commenced clinical testing of EPI-7386 in July 2020, allowing for accommodations to the planned timeline as a result of the impact of the COVID-19 situation at individual clinical trial sites (see ~~“Risk~~“Risk Factors - Risks Relating to ~~COVID-19”~~COVID-19” in our Annual report on Form 10-K).

Advancing EPI-7386 through clinical development and regulatory approval in CRPC patients

The Company is conducting an open-label, dose-escalation Phase I clinical trial to determine the safety, tolerability, pharmacokinetics, maximum tolerated dose and/or recommended Phase 2 dose (“RP2D”), and potential therapeutic benefits of the drug in mCRPC patients, who are refractory to standard-of-care treatments. The design of the Phase I clinical trial includes the standard 3+3 design per dose cohort for the Part 1a dose escalation phase, with subjects receiving a daily oral dose of EPI-7386 until there is objective evidence of clinical disease progression, and or occurrence of an unacceptable toxicity. The Part 1b dose expansion Phase will commence when the RP2D is determined.

Table of Contents

Patients for the Part 1a are initially selected clinically, on the basis of having progressive metastatic CRPC as exemplified by rising PSA values and/or radiological disease progression despite latest generation antiandrogen treatment. However, all patients are also retrospectively biologically characterized for underlying tumor genomic characteristics, for evidence of AR pathway activation and during the conduct of the trial, for dose-related biological, pharmacological and pharmacodynamic effects. The goal of the dose escalation Phase is to establish a RP2D which will be confirmed by the treatment of a larger group of patients treated at this optimal dose.

Once the Phase I clinical trial is complete, the Company plans to review the totality of the data, including the safety, tolerability, evidence of efficacy and pharmacological and biomarker data. This overall experience will inform the final size, design, and timing of a Phase II clinical trial, and importantly, the clinical as well as biological characteristics of the patients with mCRPC considered most likely to benefit from this therapeutic approach despite the late stage of their disease. Subsequent Phase II and additional clinical trials, including trials of combination aniten/lutamide therapy in earlier lines of treatment, should benefit from this initial clinical trial experience.

The Company has presented preclinical scientific data relative to EPI-7386 in a number of poster presentations at scientific ~~meetings in the past year.~~meetings.

At the 32nd EORTC-NCI-AACR Annual Symposium on Molecular Targets and Cancer Therapeutics (“ENA”) on October 24, 2020, an oral poster presentation titled, “The preclinical characterization of the N-terminal domain androgen receptor inhibitor, EPI-7386, for the treatment of prostate ~~cancer”,~~cancer,” presented new information about EPI-7386 including: (i) in an in vitro cellular thermal shift assay (CETSA), EPI-7386 was shown to physically interact with the both the full-length and the splice variant (AR-V7) form of the ~~androgen receptor (“AR”)~~AR (ii) in an in vitro full-length AR-driven cellular model (LNCaP), RNAseq data was analyzed by pathway enrichment analysis. EPI-7386 demonstrates largely similar modulation of AR-regulated genes compared to enzalutamide, but with additional unique elements; and (iii) EPI-7386 exhibits superior activity to enzalutamide in the AR-V7-driven cellular models LNCaP95 and 22Rv1 by modulating AR-driven gene expression with or without the addition of an external androgen.

Previously, in vitro data had been presented demonstrating that EPI-7386 binds to the full-length AR and can inhibit the transcription of AR-regulated genes. The new data demonstrate that EPI-7386 can also physically interact with the splice variant form, AR-V7, of the androgen receptor and inhibit its activity. The importance of this interaction with AR-V7 is seen through the superior transcriptional inhibition of AR-regulated genes by EPI-7386 compared to enzalutamide in the AR-V7-driven cell models LNCaP95 and 22Rv1. Together, these data provide insights into mechanistic aspects related to the binding and utility of EPI-7386 against AR-V7 splice-variant driven prostate cancer models. The data supports the Company’s rationale for studying EPI-7386 in men with prostate cancer resistant to current antiandrogens.

~~Advancing EPI-7386 through clinical development and regulatory approval in CRPC patients~~

The Company is conducting an open-label, dose-escalation Phase I clinical trial to determine the safety, tolerability, pharmacokinetics, maximum tolerated dose and/or recommended phase 2 dose (“RP2D”), and potential therapeutic benefits of the drug in mCRPC patients, who are refractory to standard-of-care. The design of the Phase I clinical trial includes the standard 3+3 design per dose cohort for the Part 1a dose escalation phase, with subjects receiving a daily oral dose of EPI-7386 until there is objective evidence of clinical disease progression, and or occurrence of an unacceptable toxicity. The Part 1b dose expansion phase, will commence when the RP2D is determined.

Patients for the Part 1a are initially selected clinically, on the basis of having progressive metastatic CRPC as exemplified by rising PSA values and/or radiological disease progression despite latest generation antiandrogen treatment. However, all patients are also retrospectively characterized biologically for underlying tumor genomic characteristics, for evidence of AR pathway activation and during the conduct of the trial, for dose-related biological, pharmacological and pharmacodynamic effects. The goal of the dose escalation phase is to establish a RP2D which will be confirmed by the treatment of a larger group of patients treated at this optimal dose.

~~Table of Contents~~

On February 11, 2021, the Company presented preclinical and clinical pharmacology data from ESSA’s Phase 1 clinical trial of EPI-7386 for the treatment of patients with ~~metastatic castration-resistant prostate cancer (“mCRPC”)~~mCRPC at the 2021 American Society of Clinical Oncology Genitourinary (“ASCO GU”) Cancers Symposium in an oral poster presentation titled, “Preclinical and clinical pharmacology of EPI-7386, an androgen receptor N-terminal domain inhibitor for castration-resistant prostate cancer.” The poster is available on the Company website.

Table of Contents

Data on the poster included a comparison of preclinical projections of EPI-7386 clinical pharmacokinetic parameters to the pharmacokinetic, safety and preliminary clinical data from the initial 200 mg cohort of patients enrolled in ESSA’s multi-center, open-label, ascending multiple-dose Phase 1 study of EPI-7386 to treat patients with mCRPC who have become resistant to standard of care treatments. Patients participating in this trial have progressed on two or more approved systemic therapies for mCRPC, including at least one second generation antiandrogen therapy not necessarily in the metastatic disease setting. In this initial cohort of patients receiving the 200 mg once-daily dose, EPI-7386 was well-tolerated with no SAEs observed. The results from this cohort support ESSA’s preclinical projections regarding the pharmacologic properties of EPI-7386 in humans. EPI-7386 was well-absorbed, demonstrated high exposure levels and was confirmed to have a long half-life of at least 24 hours. The predicted exposures of EPI-7386 in patients at that 200 mg dose level were similar to the Company’s modeled projections and were still below optimal target exposures of EPI-7386 associated with anti-tumor activity in animal models. Although the 200 mg dose exposure was suboptimal, one out of three patients who completed 12 weeks of therapy experienced a ~~prostate specific antigen (“PSA”)~~PSA decline of more than 50 percent after three cycles of EPI-7386 therapy (12 weeks) with ongoing continued PSA declines continuing through ~~nine~~seventeen cycles of therapy, despite previously having failed enzalutamide and abiraterone acetate.

At the 2021 American Association of Cancer Research (AACR) Annual Meeting, which took place virtually April 10-15, 2021, ESSA presented an e-poster presentation titled, “Comprehensive in vitro characterization of the mechanism of action of EPI-7386, an androgen receptor N-terminal inhibitor.” The content of this poster added to previously presented data that EPI-7386 binds to the full-length androgen receptor, inhibits the transcription of AR-regulated genes, and physically interacts with the splice variant form AR-V7, by demonstrating that EPI-7386 can prevent the androgen receptor from binding to genomic DNA and is active against additional androgen receptor splice variants, including AR-v567es. These preclinical data suggest EPI-7386 can potentially inhibit AR related transcription, a key driver of prostate cancer, and further supports the ongoing Phase 1 dose escalation ~~study which is currently dosing patients at the 1,000 mg dose level.~~study.

The data also showed that EPI-7386, in combination with enzalutamide, may result in broader and deeper inhibition of the AR pathway, underscoring the potential clinical benefit of combining EPI-7386 with current standard-of-care antiandrogen therapies for prostate cancer patients at earlier stages of the disease.

~~Table~~On October 7, 2021 at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics the Company presented a virtual poster of ~~Contents~~preclinical data confirming EPI-7386’s target engagement with the NTD of the androgen receptor, the primary driver of prostate cancer growth. The multiple studies showed (i) three separate orthogonal NMR approaches confirm that EPI-7386 binds to the Tau5 region of the NTD; (ii) cellular thermal shift assays (CETSA) confirm engagement of EPI-7386 with both full length AR (AR-FL) and AR-V567es, a splice variant lacking the ligand-binding domain (LBD); (iii) gene expression driven by the AR splice variant, AR-V567es, can be inhibited by EPI-7386 whereas enzalutamide and darolutamide, which bind to the LBD, cannot inhibit AR-V567es-driven gene expression; and (iv) chromatin immunoprecipitation sequencing (ChIP-Seq) data indicate that EPI-7386 inhibits androgen-induced changes at the AR cistrome and when combined with enzalutamide, can completely abrogate genome-wide androgen-induced AR binding.

Additionally, the data demonstrated that the combination of EPI-7386 with enzalutamide results in complete inhibition of genome-wide androgen-induced AR binding, supporting the rationale for the upcoming Phase 1/2 combination trials of EPI-7386 with approved antiandrogens in patients with metastatic castration-resistant prostate cancer.

The Company believes these results from the initial clinical data and ongoing in vitro studies are encouraging and suggest a favorable pharmacokinetic profile of EPI-7386 in patients. The Company believes the data demonstrate proof of concept by suggesting that EPI-7386, through its novel mechanism of action of targeting the N-terminal domain, may bypass the resistant mechanisms in at least a subset of mCRPC patients in whom the disease continues to remain AR-dependent despite progression on current antiandrogen therapies. While early in the Phase 1 clinical study, the Company is encouraged to have seen early signs of biological activity and declining PSA levels in a multi-refractory patient at the initial 200 mg dose as presented at the February 11, 2021 ASCO-GU meeting. EPI-7386 continues to be safe, well-tolerated, with generally good drug exposures, and adverse-events typical of those associated with antiandrogen therapy.

Table of Contents

Patients are currently being dosed at ~~600 mg, 800 mg, and~~ 1,000 mg QD, and at 800 mg/day, administered as 400 mg dosed twice daily (BID) to enhance patient drug exposures, with each of these dose levels being cleared as safe and tolerable. Given the favorable tolerability of the drug and the wide therapeutic window seen in preclinical studies, the Company plans to enroll additional higher dose cohorts using a twice daily (BID) dosing schedule to further enhanceA patient ~~drug exposures. In addition, the Company is planning to file a~~cohort at 1,200 mg/day, administered as 600 mg BID, has begun dosing. The protocol amendment ~~to focus further~~filed with the FDA in September 2021 allows for monotherapy development in less heavily pretreated patients in whom the Company believes the androgen receptor pathway continues to be the primary driver of tumor growth. The Company’s goal is to establish, ~~a recommended Phase 2 dose (“RP2D”) for monotherapy during~~in the first half of 2022, one or more doses/schedules to be tested in the expansion Phase 1b study in alignment with the FDA Project Optimus guidance. This recommended dose or doses will be based on multiple inputs, including pharmacokinetic and biological observations, in addition to clinical ~~experience, and commence the expansion Phase 1b study soon thereafter in earlier, less heavily pre-treated and more biologically characterized patients.~~experience. It is expected that a clinical readout of the Phase 1a monotherapy trial will be presented in the first half of calendar 2022.” The expansion Phase 1b study is expected to commence in the second half of 2022 and will confirm a RP2D.

Developing a product candidate as an essential component of a new standard of care for the treatment of pre-CRPC and expanding usage earlier in the disease stage

An activated AR is required for the growth and survival of most prostate cancer. Unlike current antiandrogen therapies which can only inhibit full-length AR, NTD inhibition of AR-directed biology occurs both in full length AR and splice variant ARs. Therefore, the Company believes that the AR-NTD is an ideal target for next-generation antiandrogen hormone therapy. If ESSA’s product candidate is successful in treating CRPC patients, it is reasonable to expect that such clinical candidate may be effective in treating earlier stage patients. Preclinical studies suggest particular value to the use of anitens in combination with the ~~currently-widely~~currently widely used antiandrogens. As a result, the Company intends to conduct additional clinical studies potentially leading to the approval of EPI-7386 for use in prostate cancer patients at an earlier disease stage in combination with second-generation antiandrogens. In this regard, the Company continues to develop in vitro and in vivo data in collaboration with academic investigators and clinical data with industry investigators as in the collaboration with Janssen to study EPI-7386 in combination clinical trials with abiraterone acetate/prednisone, as well as with apalutamide, and in the collaboration and supply agreement with Astellas to evaluate EPI-7386 in combination with Astellas and Pfizer Inc.’s enzalutamide, as well as in the collaboration and supply agreement with Bayer to evaluate EPI-7386 in combination with Bayer’s darolutamide, in patients with mCRPC. Preclinical data supporting this approach ~~supports~~highlights the potential benefits of combining an NTD inhibitor, such as an ~~Aniten~~aniten compound, with an antiandrogen that works through inhibition of the LBD of the AR by directly blocking androgen binding (e.g. lutamides) or by inhibiting androgen synthesis (abiraterone acetate). Other emerging potential clinical applications for NTD inhibitors are in combination with other agents, such as poly ADP ribose polymerase (“PARP”) inhibitors, Pin1 inhibitors, CDK4/6 inhibitors, as well as in the subset of metastatic breast cancer patients whose tumors have been demonstrated to have activation of the AR pathway.

As part of the continued preclinical work on Aniten compounds, the Company has studied NTD degraders and presented data for its first generation of AR Aniten based chimera (“ANITAC”) NTD degraders at the AACR annual meeting on April 10, 2022 in a poster titled “Androgen receptor (AR) N-Terminal Domain degraders can degrade AR full length and AR splice variants in CRPC preclinical models”. The preclinical data demonstrate the potential of ESSA’s ANITAC degraders as a new approach to AR pathway inhibition. The intrinsically disordered nature of the NTD region of the AR has meant it has generally been considered undruggable. The preclinical studies have shown that through their unique ability to bind to the NTD of AR, ANITACs have the ability to inhibit NTD-mediated AR transcription while also degrading AR protein including resistant forms of AR which are commonly associated with castration-resistant prostate cancer.

The preclinical results demonstrate that ANITAC degraders utilize the ubiquitin proteasome system and can degrade many forms of AR including full length, mutant, and splice variants which are often expressed in CRPC patients. Specifically, the ANITAC degraders show robust potency in inhibiting AR transcriptional activity driven by AR-FL, AR-V7, or AR-V567es. In addition, the orally-bioavailable ANITAC degraders exhibit high potency in inhibiting AR-dependent transcription and reducing viability of AR-dependent prostate cancer cells.

Table of Contents

Evaluating strategic collaborations to maximize value

The Company currently retains all commercial rights for its ~~EPI and Aniten~~aniten series drug portfolio. The Company continues to evaluate potential collaborations that could enhance the value of its prostate cancer program and allow it to leverage the expertise of such strategic collaborators such as those with Janssen, Astellas, and Bayer.

~~Table of Contents~~

Future Clinical Development Program

Phase I/II Clinical Trial Design for treating CRPC patients

With the allowance by the FDA of the IND and clearance of the CTA by Health Canada for EPI-7386, the Company is conducting a Phase I, multi-dose escalation clinical trial to determine the safety, tolerability, maximum tolerated dose/recommended Phase 2 dose pharmacokinetics, and efficacy of the compound in ~~CRPC~~refractory mCRPC patients at clinical sites in the US and Canada. The clinical trial is expected to enroll approximately 3042 patients at multiple medical institutions in a standard 3+3 trial design with an approximate 1012 additional patients enrolled in a dose expansion cohort at the recommended Phase 2 dose level. The Company is working with clinicals sites so patients can be enrolled ensuring compliance with COVID-19 risk management guidance as provided by FDA (see ~~“Risk~~“Risk Factors - Risks Relating to ~~COVID-19”~~COVID-19” in our Annual Report on Form 10-K). Learnings from the Phase I clinical trial of EPI-506 have been incorporated into the design and conduct of the Phase I study. The Company has included in the study design, for example, extensive biological characterization of the patients entered into the trial. Depending on the results of the Phase 1 study, a Phase II single arm clinical trial evaluating the activity of EPI-7386 single agent in a larger group of biologically-characterized mCRPC patients might be conducted.

In October 2021 the company disclosed the development of a collaboration with Caris Life Sciences, involving the incorporation of Caris’ newly developed cNAS (“circulating nucleic acid sequencing”) assay in the characterization of patients receiving EPI-7386. The Company believes that the characterization of real time individual patient biology will contribute significantly to understanding the extent to which individual patient’s tumors are still AR driven and what mechanisms of resistance exist.

Early Conduct of a Combination Phase I/II Clinical Trial

Given the evolution of prostate cancer therapeutics towards combination therapy strategies from the earlier stages of the disease, the biological rationale for combining NTD and LBD inhibitors, and compelling early in vitro and preclinical animal model results, the Company intends to perform combination studies of ~~the next-generation Aniten compound~~EPI-7386 with current generation ~~antiandrogens following the Phase 1 dose escalation and expansion studies.~~antiandrogens. Since these combination studies will involve earlier lines of therapy, they will commence only after sufficient experience with safety, tolerability and efficacy has been accumulated with single agent EPI-7386 therapy in patients with metastatic disease resistant to standard of care treatments. Under the collaboration agreement with Janssen, Janssen will pay for and conduct ~~the trial,~~two trials with EPI-7386 and each of their antiandrogens, apalutamide and abiraterone acetate, and ESSA will provide the clinical trial material of EPI-7386. Under the collaboration with Astellas, ESSA will pay for and conduct a trial with EPI-7386 and enzalutamide, with Astellas providing enzalutamide, and under the collaboration with Bayer, Bayer will pay for and conduct a clinical trial with EPI-7386 and darolutamide, with ESSA providing the clinical trial material EPI-7386, in patients with mCRPC. The ESSA-managed clinical trial collaboration with Astellas (enzalutamide) will begin in the fourth quarter of calendar 2021. The combination studies with Janssen and Bayer are anticipated to begin in late 2021 or early 2022.EPI-7386.

Once the RP2D for each drug has been established, Phase 2 of the study will commence. Phase 2 is a two-arm, randomized (2:1), open-label study and is expected to enroll 120 mCRPC patients who have not yet been treated with second-generation antiandrogen therapies. The goal of the Phase 2 of the study that will be conducted by ESSA is to evaluate the safety, tolerability and anti-tumor activity of EPI-7386 in combination with a fixed dose of enzalutamide compared with enzalutamide as a single agent.

Table of Contents

Phase III Clinical Trial

In order to ultimately obtain full single agent regulatory approval, the Company expects that at least one Phase III clinical trial will be required, most likely in patients similar to the population of mCRPC patients who will have been enrolled in the planned Phase I/II clinical trial. However, the results of the Phase I/II clinical trial may also suggest modification of the initial patient population based on anti-tumor response and biomarker assessment. In a Phase III clinical trial, the key end-point is expected to be progression-free survival or overall survival relative to patients receiving the standard-of-care. It is expected that such a Phase III clinical trial would be conducted at numerous sites around the world.

~~Table of Contents~~

Competition

The competition in the prostate cancer market is very high, and many of the companies against which we compete or against which we may compete in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Several pharmaceutical therapies already have approved and many new molecules are being tested for their effect in this patient population. In addition, generic forms of Zytiga (abiraterone acetate) are now approved and commercially available in the U.S.

Currently approved therapies include:


GENERIC/PROGRAM NAME	BRAND NAME	COMPANY NAME(S)	STAGE
Enzalutamide	Xtandi	Astellas and Pfizer	Marketed
Abiraterone acetate	Zytiga	Johnson & Johnson	Marketed
Sipuleucel-T	Provenge	Valeant	Marketed
Docetaxel	n/a	Sanofi and various	Marketed
Cabazitaxel	Jevtana	Sanofi	Marketed
Radium-233	Xofigo	Bayer	Marketed
Apalutamide (ARN-509)	Erleada	Johnson & Johnson	Marketed
Darolutamide	Nubeqa	Bayer	Marketed
Pembrolizumab	Keytruda	Merck	Marketed
Olaparib	Lynparza	AstraZeneca	Marketed
Rucaparib	Rubraca	Clovis Oncology	Marketed

In this market, ESSA believes that its competitive position is strong because its product candidate, if successful, involves a mechanistically unique, differentiated approach to prostate cancer involving the therapeutic modality that has been shown to make the biggest difference to the survival of recurrent prostate cancer patients: blocking AR activation. Since ~~EPI compounds~~anitens have been shown to directly ~~block the~~bind to AR-NTD and prevent AR-mediated transcription, they have the potential to bypass the AR-dependent resistance pathways (discussed above) that may develop as a result of treatment with current hormone-related therapies that target the AR LBD. If successful, ESSA believes this could represent a significant step forward in the treatment of prostate cancer. To ESSA’s knowledge, no other antagonist to the AR-NTD is currently undergoing clinical trials for prostate cancer or any other indication. Other approaches to interfering with AR signaling include strategies to degrade the AR such as that being pursued by Arvinas, Inc.

Patents and Proprietary Rights

License Agreement with UBC and the BCCA

ESSA has in-licensed intellectual property embodied in issued patents, pending patents applications and know-how relating to compounds that modulate AR ~~activity created through research work done at UBC and the BCCA (together, the “Licensors”) under the direction of Dr. Raymond Andersen and Dr. Marianne Sadar, respectively.~~activity. ESSA refers to these intellectual property rights as the “Licensed ~~IP”.~~IP.”

Table of Contents

Pursuant to the License Agreement, ESSA has been granted a worldwide, exclusive license to develop and commercialize products based on the Licensed IP. ESSA paid a minimum annual royalty of C$40,000 in the 2014 calendar year, increasing to C$65,000 in each of 2015 and 2016 and C$85,000 in 2017, 2018, and 2019 and must continue to pay a minimum of C$85,000 for each year thereafter. For a First Compound entering clinical development, an additional C$50,000 and C$900,000 must be paid upon enrollment of a patient in a Phase II and Phase III clinical trial, respectively.

~~Table of Contents~~

The Licensors may terminate the License Agreement upon ESSA’s insolvency, or the License Agreement may be terminated by either party for certain material breaches by the other party. ESSA has already spent more than C$5,000,000 in connection with the commercialization of products relating directly to the Licensed IP, as required under the License Agreement. ESSA is required to allocate reasonable time to the development and commercialization of the Licensed IP and to use reasonable efforts to promote, market and sell products covered by the Licensed IP. The terms of the License Agreement required ESSA to issue to the Licensors, 1,000,034 pre-Consolidation common shares, in lieu of payment of an initial license fee. If ESSA develops products covered by the Licensed IP in the future, it will be required to pay certain development and regulatory milestone payments up to an aggregate of C$2.4 million for the first drug product developed under the license and up to an aggregate of C$510,000 for each subsequent product. ESSA must also pay the Licensors low single-digit royalties based on aggregate worldwide net sales of products covered by the Licensed IP and a percentage of sublicensing revenue in the low teens. ~~ESSA is also required to reimburse costs incurred by the Licensors related to the prosecution and maintenance of patents embodying the Licensed IP.~~ The License Agreement will expire on the later of 20 years after the date of the License Agreement or the expiry of the last issued patent included in the Licensed IP.

ESSA’s Intellectual Property Strategy

Both ESSA and the broader pharmaceutical industry attach significant importance to patents for the protection of new technologies, products and processes. Accordingly, ESSA’s success depends, in part, on its ability to obtain patents or rights thereto, to protect commercial secrets and carry on activities without infringing the rights of third parties. See ~~“Risk Factors”~~“Risk Factors” in our Annual Report on Form 10-K. Where appropriate, and consistent with management’s objectives, ~~patents are pursued once concepts have been validated through appropriate laboratory work. To that end,~~ ESSA will continue to seek patents in relation to ~~those~~ components or concepts of its technology that it perceives to be important.

Patent Applications

ESSA has licensed certain patent rights, with respect to some of its compounds that modulate AR activity, from the ~~Licensors, jointly.~~Licensors. ESSA has the right to acquire ownership of the licensed patents and patent applications upon specified payment to the Licensors, and providing that payments required under the License Agreement continue to be made.

As of March 2022, ESSA ~~currently has 16 pending~~owns rights to 48 issued patents worldwide, including 13 issued U.S. patents, that are in force and ~~maintained patent families which~~ cover multiple EPI- and ~~Aniten~~aniten structural classes of compounds with different structural motifs/~~analogues, that~~analogues. As of March 2022, 5 of these issued patents cover the EPI-7386 compound, and are expected to provide ~~a strong and defensive intellectual property portfolio.~~protection between 2036 to 2041.

Regulatory Environment

The production and manufacture of ESSA’s product candidate and potential future product candidates and its R&D activities are subject to regulation for safety, efficacy, quality and ethics by various governmental authorities around the world. In the United States, drugs and biological products are subject to regulation by the FDA. In Canada, these activities are regulated by the Food and Drugs Act and the rules and regulations thereunder, which are enforced by the TPD. Drug approval laws require registration of manufacturing facilities, carefully controlled research and testing of product candidates, government review and approval of experimental results prior to giving approval to sell drug products. Regulators also require that rigorous and specific standards such as cGMP, ~~GLP~~good laboratory practices (“GLP”) and ~~GCP~~current good clinical practices (“GCP”) are followed in the manufacture, testing and clinical development respectively of any drug product. See ~~“Risk Factors”~~“Risk Factors” in our Annual Report on Form 10-K.

3435

Table of Contents

The process of obtaining regulatory approvals and the corresponding compliance with appropriate federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval may subject an applicant or sponsor to a variety of administrative or judicial sanctions, including refusal by the FDA to approve pending applications, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters and other types of enforcement letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement of profits, or civil or criminal investigations and penalties brought by the FDA and the Department of Justice or other governmental entities.

Drug Products Development Process

An applicant seeking approval to market and distribute a new drug product in the United States must typically undertake the following:

●

completion of extensive nonclinical, sometimes referred to as preclinical laboratory tests, and preclinical animal trials in compliance with applicable requirements for the humane use of laboratory animals and formulation studies, including GLPs;

●

submission to the FDA of an IND, which must take effect before human clinical trials may begin;

●

approval by an ~~IRB,~~institutional review board (“IRB”), representing each clinical site before each clinical trial may be initiated;

●

performance of adequate and well-controlled human clinical trials according to the FDA’s regulations commonly referred to as GCP regulations and any additional requirements for the protection of human research subjects and their health information, to establish the safety and efficacy of the proposed drug product for its intended use;

●

preparation and submission to the FDA of a New Drug Application (“NDA”);

●

review of the product by an FDA advisory committee, where appropriate or if applicable;

●

satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities at which the product, or components thereof, are produced to assess compliance with cGMP requirements and to assure that the facilities, methods and controls are adequate to preserve the product’s identity, strength, quality and purity;

●

payment of user fees and securing FDA approval of the NDA; and

●

compliance with any post-approval requirements, including Risk Evaluation and Mitigation Strategies (“REMS”) and post-approval studies required by the FDA.

In addition to regulations in the United States, we will be subject to a variety of regulations in other jurisdictions governing, among other things, clinical studies and any commercial sales and distribution of our products.

Whether or not we obtain FDA approval for a product, we must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical studies or marketing of the product in those countries. Certain countries outside of the United States have a similar process that requires the submission of a clinical study application much like the IND prior to the commencement of human clinical studies. In the European Union, for example, a CTA must be submitted to each country’s national health authority and an independent ethics committee, much like the FDA and IRB, respectively. Once the CTA is approved in accordance with a country’s requirements, clinical study development may proceed.

The requirements and process governing the conduct of clinical studies, product licensing, coverage, pricing and reimbursement vary from country to country. In all cases, the clinical studies are conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.

Table of Contents

Preclinical Studies

Preclinical studies are conducted in vitro and in animals to evaluate pharmacokinetics, metabolism and possible toxic effects to provide evidence of the safety of the product candidate prior to its administration to humans in clinical studies and throughout development. The conduct of preclinical studies is subject to federal regulations and requirements, including GLP regulations. The results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and plans for clinical studies, among other things, are submitted to the FDA as part of an IND. Some long-term preclinical testing, such as animal tests of reproductive adverse events and carcinogenicity, may continue after the IND is submitted.

~~Table of Contents~~

Initiation of Human Testing

Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with GCP requirements, which include, among other things, the requirement that all research subjects provide their informed consent in writing before their participation in any clinical trial. Clinical trials are conducted under written trial protocols detailing, among other things, the objectives of the trial, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to a proposed clinical trial and places the trial on clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. In Canada, this application is called a CTA. An IND/CTA application must be filed and accepted by the FDA or TPD, as applicable, before human clinical trials may begin. In addition, an IRB representing each institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution, and the IRB must conduct continuing review and reapprove the trial at least annually. The IRB must review and approve, among other things, the trial protocol and informed consent information to be provided to trial subjects. An IRB must operate in compliance with FDA regulations.

Two key factors influencing the rate of progression of clinical trials are the rate at which patients can be enrolled to participate in the research program and whether effective treatments are currently available for the disease that the drug is intended to treat. Patient enrollment is largely dependent upon the incidence and severity of the disease, the treatments available and the potential side effects of the drug to be tested and any restrictions for enrollment that may be imposed by regulatory agencies.

Phase I Clinical Trials

Phase I clinical trials for cancer therapeutics are typically conducted on a small number of patients to evaluate safety, dose limiting toxicities, tolerability, pharmacokinetics and to determine the dose for Phase II clinical trials in humans.

Phase II Clinical Trials

Phase II clinical trials typically involve a larger patient population than Phase I clinical trials and are conducted to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of a product candidate for specific targeted diseases and to determine dosage tolerance, optimal dosage and dosing schedule.

Phase III Clinical Trials

Phase III clinical trials typically involve testing an experimental drug on a much larger population of patients suffering from the targeted condition or disease – in ESSA’s case, CRPC. These studies involve testing the experimental drug in an expanded patient population at geographically dispersed test sites (multi-center trials) to establish clinical safety and effectiveness. These trials also generate information from which the overall risk-benefit relationship relating to the drug can be determined.

3637

Table of Contents

In most cases FDA requires two adequate and well controlled Phase III clinical trials to demonstrate the efficacy of the drug. A single Phase III trial with other confirmatory evidence may be sufficient in rare instances where the trial is a large multicenter trial demonstrating internal consistency and a statistically very persuasive finding of a clinically meaningful effect on mortality, irreversible morbidity or prevention of a disease with a potentially serious outcome and confirmation of the result in a second trial would be practically or ethically impossible.

New Drug Application

Assuming successful completion of required clinical testing and other requirements, the results of the preclinical and clinical studies, together with detailed information relating to the product’s chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of an NDA, or the TPD as part of a New Drug Submission (“NDS”), requesting approval to market the drug product for one or more indications. The NDS or NDA is then reviewed by the applicable regulatory body for approval to market the drug.

The FDA conducts a preliminary review of an NDA within 60 days of its receipt and informs the sponsor by the 74th day after the FDA’s receipt of the submission to determine whether the application is sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event, the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review. The FDA has agreed to specified performance goals in the review process of NDAs. Most such applications are meant to be reviewed within ten months from the date of filing, and most applications for “priority review” products are meant to be reviewed within nine months of filing. The review process may be extended by the FDA for three additional months to consider new information or clarification provided by the applicant to address an outstanding deficiency identified by the FDA following the original submission.

Before approving an NDA, the FDA typically will inspect the facility or facilities where the product is or will be manufactured. These pre-approval inspections cover all facilities associated with an NDA submission, including drug component manufacturing (such as Active Pharmaceutical Ingredients), finished drug product manufacturing, and control testing laboratories. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP.

The cost of preparing and submitting an NDA is substantial. The submission of most NDAs is additionally subject to a substantial application user fee, currently exceeding $2,500,000 and the manufacturer or sponsor under an approved new drug application are also subject to significant annual program and establishment user fees. These fees are typically increased annually.

On the basis of the FDA’s evaluation of the NDA and accompanying information, including the results of the inspection of the manufacturing facilities, the FDA may issue an approval letter or a complete response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A complete response letter generally outlines the deficiencies in the submission and may require substantial additional testing or information in order for the FDA to reconsider the application. If and when those deficiencies have been addressed to the FDA’s satisfaction in a resubmission of the NDA, the FDA will issue an approval letter. The FDA has committed to reviewing such resubmissions in two or nine months depending on the type of information included. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.

3738

Table of Contents

If the FDA approves a product, it may limit the approved indications for use for the product, require that contraindications, warnings or precautions be included in the product labeling, require that post-approval studies, including Phase 4 clinical trials, be conducted to further assess the drug’s safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution restrictions or other risk management mechanisms which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-market studies or surveillance programs. After approval, many types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval.

Post-Approval Requirements

Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse experiences with the product. After approval, significant changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing, annual user fee requirements for any marketed products and the establishments at which such products are manufactured, as well as new application fees for supplemental applications with clinical data.

In addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and state agencies, and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance.

Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things:

●

restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;

●

fines, warning letters or holds on post-approval clinical trials;

●

refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product license approvals;

●

product seizure or detention, or refusal to permit the import or export of products; or

●

injunctions or the imposition of civil or criminal penalties.

The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability.

In addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act, or PDMA, which regulates the distribution of drugs and drug samples at the federal level, and sets minimum standards for the registration and regulation of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples and impose requirements to ensure accountability in distribution.

3839

Table of Contents

Orphan Designation and Exclusivity

ESSA may, in the future, seek orphan drug designation for its product candidates. Under the Orphan Drug Act, the FDA may designate a drug product as an “orphan drug” if it is intended to treat a rare disease or condition (generally meaning that it affects fewer than 200,000 individuals in the United States, or more in cases in which there is no reasonable expectation that the cost of developing and making a drug product available in the United States for treatment of the disease or condition will be recovered from sales of the product). A company must request orphan product designation before submitting an NDA. If the request is granted, the FDA will disclose the identity of the therapeutic agent and its potential use. Orphan product designation does not convey any advantage in or shorten the duration of the regulatory review and approval process.

If a product with orphan status receives the first FDA approval for the disease or condition for which it has such designation, the product generally will receive orphan product exclusivity. Orphan product exclusivity means that the FDA may not approve any other applications for the same product for the same indication for seven years, except in certain limited circumstances. Competitors may receive approval of different products for the indication for which the orphan product has exclusivity and may obtain approval for the same product but for a different indication. If a drug or drug product designated as an orphan product ultimately receives marketing approval for an indication broader than what was designated in its orphan product application, it may not be entitled to exclusivity.

Developments

~~Significant Business~~Recent Developments ~~for~~

At the ~~Three Months Ended June 30, 2021~~

~~On April 10, 2021, at the~~October 2021 American Association for Cancer Research (“AACR”), National Cancer Institute (“NCI”), and European Organisation for Research and Treatment of Cancer ~~Research (AACR) Annual Meeting,~~(“EORTC”) Virtual International Conference on Molecular Targets and Cancer Therapeutics, the Company presented ~~an e-poster presentation titled, “Comprehensive in vitro characterization of~~preclinical data characterizing the mechanism of action of EPI-7386, ~~an androgen receptor N-terminal inhibitor.”~~including the results of NMR studies which confirm the binding of the compound to the NTD of the AR, a region not currently targeted by other antiandrogen therapies. The ~~poster is available on~~data also demonstrate that the ~~Company website.~~

combination of EPI-7386 with enzalutamide results in complete inhibition of genome-wide androgen-induced AR binding, supporting the rationale for Phase 1 / 2 combination trials of EPI-7386 with approved antiandrogens in patients with mCRPC.

On ~~April 23, 2021, the Company renewed a lease agreement for the Houston office effective August 1, 2021 through July 31, 2023 with an option to renew for an additional 2 years.~~

~~On April 28, 2021,~~January 19, 2022, the Company announced ~~that it had entered into a clinical trial collaboration and supply agreement with Bayer to evaluate EPI-7386~~the first patient dosed in ~~combination with Bayer’s androgen receptor inhibitor, darolutamide, in patients with mCRPC. Under~~ the ~~terms of the agreement, following review of certain clinical data, Bayer may sponsor and conduct a~~Company-sponsored Phase 1/2 study to evaluate the safety, tolerability ~~pharmacokinetics~~ and preliminary efficacy of ESSA’s lead product candidate, EPI-7386, a first-in-class N-terminal domain androgen receptor inhibitor, in combination with Astellas and Pfizer Inc.’s ligand-binding domain androgen receptor inhibitor, enzalutamide, in patients with metastatic castration-resistant prostate cancer (“mCRPC”). This combination trial investigates the potential clinical benefit of inhibiting the androgen receptor through two independent pathways in the treatment of patients with mCRPC who have not yet received treatment with a second-generation antiandrogen drug. In preclinical models, the combination of EPI-7386 with lutamides by simultaneously targeting both ends of the AR resulted in deeper and ~~darolutamide~~broader inhibition of androgen biology.

The Phase 1/2 clinical trial (NCT05075577) is a two part study. The Phase 1 part of the study evaluates the safety and tolerability of the drug combination to establish the recommended Phase 2 doses for EPI-7386 and enzalutamide when dosed in combination. This Phase of the study is expected to enroll up to 30 mCRPC patients who have not yet been treated with second-generation antiandrogen therapies. In the Phase 2 part of the study single agent enzalutamide is compared to the combination of enzalutamide and EPI-7386 in the same patient population. The goal of the Phase 2 part of the study is to evaluate the safety, tolerability and anti-tumor activity of EPI-7386 in combination with a fixed dose of enzalutamide compared with enzalutamide as a single agent. This part of the study is expected to enroll 120 mCRPC patients who have not yet been treated with second-generation antiandrogen therapies.

Table of Contents

At the AACR annual meeting on April 10, 2022, the Company presented preclinical data for its first generation of androgen receptor (AR) ANITen bAsed Chimera (ANITAC™) N-terminal domain (NTD) degraders. The preclinical results demonstrate that ANITAC degraders utilize the ubiquitin proteasome system and can degrade many forms of AR including full length, mutant and splice variant which are often expressed in CRPC patients. ~~ESSA will supply EPI-7386 for~~Specifically, the ~~trial~~ANITAC degraders show robust potency in inhibiting AR transcriptional activity driven by AR-FL, AR-V7, or AR-V567es. In addition, the orally-bioavailable ANITAC degraders exhibit high potency in inhibiting AR-dependent transcription and ~~will retain all rights to EPI-7386.~~reducing viability of AR-dependent prostate cancer cells.

ESSA has never been profitable and has incurred net losses since inception. ESSA’s net losses were ~~$28,245,962~~$20,001,254 and ~~$18,892,028~~$19,493,951 for the ~~nine~~six months ended ~~June 30,~~March 31, 2022, and 2021 ~~and 2020~~ respectively. ESSA expects to incur losses for the foreseeable future, and it expects these losses to increase as it continues the development of, and seek regulatory approvals for, its product candidate. Because of the numerous risks and uncertainties associated with product development, ESSA is unable to predict the timing or amount of increased expenses or when, or if, it will be able to achieve or maintain profitability.

~~Table of Contents~~

Selected Quarterly Financial Information

The following table sets forth ESSA’s unaudited consolidated financial data for each of the last eight quarters, prepared in accordance with U.S. GAAP. The Company has not earned any revenues or declared dividends as of ~~June 30, 2021:~~March 31, 2022:


	For the Quarters Ended								For the Quarters Ended
	June 30,		March 31,		December 31,		September 30,		March 31,		December 31,		September 30,		June 30,
	2021		2021		2020		2020		2022		2021		2021		2021
Research and development expense	$	6,231,908	$	7,268,257	$	4,485,772	$	2,236,680	$	7,649,459	$	6,019,759	$	6,273,052	$	6,231,908
General and administration		3,117,900		4,615,332		2,208,917		2,200,159		3,817,370		3,062,170		2,942,432		3,117,900
Comprehensive income (loss)		(8,752,011)		(12,965,247)		(6,528,704)		(4,553,342)		(10,903,335)		(9,097,919)		(8,559,499)		(8,752,011)
Basic and diluted earnings (loss) per share		(0.21)		(0.36)		(0.20)		(0.17)		(0.25)		(0.21)		(0.19)		(0.21)
Cash and cash equivalents		145,194,181		151,562,303		52,484,512		56,320,763		86,235,830		121,058,121		137,825,024		145,194,181
Short-term investments		57,068,822		57,034,921		22,016,344		22,011,337		94,782,609		68,141,166		57,102,159		57,068,822
Total assets		203,524,045		210,001,054		76,174,988		80,574,565		182,609,005		191,486,181		198,165,818		203,524,045
Long-term liabilities		817,735		1,413,292		38,246		127,376		145,268		288,971		230,603		817,735
Working capital		199,949,211		206,202,601		73,861,974		79,038,442		178,353,354		187,291,085		193,668,414		199,949,211


	For the Quarters Ended								For the Quarters Ended
	June 30,		March 31,		December 31,		September 30,		March 31,		December 31,		September 30,		June 30,
	2020		2020		2019		2019		2021		2020		2020		2020
Research and development expense	$	2,703,704	$	4,618,436	$	2,587,148	$	2,004,750	$	7,268,257	$	4,485,772	$	2,236,680	$	2,703,704
General and administration		2,171,020		4,863,608		2,139,165		1,246,426		4,615,332		2,208,917		2,200,159		2,171,020
Comprehensive income (loss)		(4,924,828)		(9,353,927)		(4,613,273)		(3,327,117)		(12,965,247)		(6,528,704)		(4,553,342)		(4,924,828)
Basic and diluted earnings (loss) per share		(0.24)		(0.45)		(0.22)		(0.23)		(0.36)		(0.20)		(0.17)		(0.24)
Cash and cash equivalents		36,482,049		39,913,569		45,934,420		53,322,723		151,562,303		52,484,512		56,320,763		36,482,049
Short-term investments		-		-		-		-		57,034,921		22,016,344		22,011,337		-
Total assets		38,100,438		41,603,369		47,168,317		54,573,093		210,001,054		76,174,988		80,574,565		38,100,438
Long-term liabilities		76,762		40,477		99,766		16,520		1,413,292		38,246		127,376		76,762
Working capital		36,475,762		39,746,147		45,527,165		48,724,264		206,202,601		73,861,974		79,038,442		36,475,762

4041

Table of Contents

Results of Operations for the ~~Nine~~Six Months Ended ~~June 30,~~March 31, 2022 and 2021 ~~and 2020~~

There was no revenue in any of the periods ended as reported. The Company incurred a comprehensive loss of ~~$28,245,962~~$20,001,254 for the ~~nine~~six months ended ~~June 30, 2021~~March 31, 2022 compared to a comprehensive loss of ~~$18,892,028~~$19,493,951 for the ~~nine~~six months ended ~~June 30, 2020.~~March 31, 2021. Variations in ESSA’s expenses and net loss for the periods resulted primarily from the following factors:

Research and Development Expenditures

R&D expense included the following major expenses by nature:


	Three months ended				Nine months ended				Three months ended				Six months ended
	June 30, 2021		June 30, 2020		June 30, 2021		June 30, 2020		March 31, 2022		March 31, 2021		March 31, 2022		March 31, 2021
Clinical	$	1,156,860	$	548,639	$	4,213,305	$	1,158,819	$	1,112,940	$	1,740,573	$	1,972,586	$	3,056,445
Consulting		225,180		50,787		519,286		183,216		139,499		205,747		282,095		294,106
Legal patents and license fees		346,366		214,400		663,219		642,092		202,942		248,310		509,582		316,853
CMC		1,409,283		650,760		5,516,377		2,583,331		1,838,612		2,654,734		2,866,647		4,107,094
Other		35,904		(872)		82,235		100,412		39,368		38,982		55,770		46,331
Preclinical and data analysis		1,268,068		574,861		3,231,017		2,450,292		2,357,100		961,487		4,131,305		1,962,949
Research grants and administration		-		-		157,080		153,379		-		157,080		-		157,080
Royalties		-		-		66,759		65,186		66,805		66,759		82,485		66,759
Salaries and benefits		546,455		285,430		1,209,060		978,792		639,302		401,556		1,146,817		662,605
Share-based payments		1,243,792		382,941		2,323,185		1,564,835		1,121,859		791,969		2,381,210		1,079,393
Travel and other		-		(3,242)		4,414		28,934		131,032		1,060		240,721		4,414
Total	$	6,231,908	$	2,703,704	$	17,985,937	$	9,909,288	$	7,649,459	$	7,268,257	$	13,669,218	$	11,754,029

The overall R&D expense for the ~~nine~~six months ended ~~June 30, 2021~~March 31, 2022 was ~~$17,985,937~~$13,669,218 compared to ~~$9,909,288~~$11,754,029 for the ~~nine~~six months ended ~~June 30, 2020~~March 31, 2021 and includes non-cash expense related to share-based payments expense of ~~$2,323,185 (2020~~$2,381,210 (2021 - ~~$1,564,835)~~$1,079,393). R&D expense in the ~~nine-month~~six-month period ended ~~June 30, 2021~~March 31, 2022 reflects the ongoing clinical trial of EPI-7386. R&D expense in the ~~period~~six-month periods ended ~~June 30, 2020 was incurred primarily~~March 31, 2022 and 2021 reflects the ongoing clinical trial of EPI-7386 which commenced in ~~preclinical research with work directed to the completion of the IND filing in March 2020 and chemistry and manufacturing cost in preparation for the Phase 1 study.~~July 2020.

The share-based payments expense of ~~$2,323,185 (2020~~$2,381,210 (2021 - ~~$1,564,835)~~$1,079,393), which is a non-cash expense, relates to the value assigned to stock options and employee share purchase rights granted to key management and consultants of the Company. The expense is recognized in relation to the grant and vesting of these equity instruments, net of expiries and forfeitures, and allocated to research and development, general and administration and financing expenditures relative to the activity of the underlying optionee.

Clinical costs of ~~$4,213,305 (2020~~$1,972,586 (2021 - ~~$1,158,819)~~$3,056,445) were generated in relation to expenditures with the Company’s clinical research organizations conducting the Phase 1 clinical trial of EPI-7386. In the prior period, the costs related to clinical consulting work in preparation and completion of the IND and CTA filings and preparation for the Phase 1 clinical trial of EPI-7386 which began in July 2020.

Preclinical and data analysis costs of ~~$3,231,017 (2020~~ $4,131,305 (2021 – ~~$2,450,292)~~$1,962,949) were ~~incurred~~generated in ~~the identification of the lead compound EPI-7386 in 2019 and the subsequent filing of the IND in 2020. In the current period, the amount includes~~relation to expenditures for pharmacokinetic data analysis on data from the clinical trial related to the Phase I study.

CMC costs of ~~$5,516,377 (2020~~$2,866,647 (2021 - ~~$2,583,331)~~$4,107,094) included costs incurred in formulation and chemistry work around the Company’s pharmaceutical characteristics of EPI-7386. CMC costs include cGMP manufacturing of EPI 7386 drug supply to support the ongoing clinical trial. In

Consulting costs were $282,095 for the ~~nine~~six months ended ~~June 30, 2021, costs were incurred in formulation~~March 31, 2022 (2021 - $294,106) relating to contract project management services and ~~chemistry work around the Company’s pharmaceutical characteristics of EPI-7386.~~collaborations.

4142

Table of Contents

Consulting costs increased to $519,286 for the nine months ended June 30, 2021 (2020 - $183,216) relating to contract project management services. In the comparative period, costs were related to consulting fees for scientific advisors in connection with candidate selection and preparation of the IND filing, including contract project management services.

Legal patents and license fees for the period totaled ~~$663,219 (2020~~$509,582 (2021 - ~~$642,092)~~$316,853). The Company has adopted a tiered patent strategy to protect its intellectual property as the pharmaceutical industry places significant importance on patents for the protection of new technologies, products and processes. The costs reflect that ongoing investment and timing of associated maintenance costs. The Company anticipates that there will be continued investment into patent applications.

General and Administration Expenditures

General and administrative expenses include the following major expenses by nature:


	Three months ended		Three months ended		Nine months ended		Nine months ended		Three months ended				Six months ended
	June 30, 2021		June 30, 2020		June 30, 2021		June 30, 2020		March 31, 2022		March 31, 2021		March 31, 2022		March 31, 2021
Amortization	$	25,503	$	27,580	$	80,665	$	82,742	$	95,505	$	27,581	$	125,952	$	55,162
Consulting and subcontractor fees		73,478		26,357		157,274		91,087		80,375		34,318		144,057		83,796
Director fees		84,750		101,250		271,055		303,750		84,750		92,805		169,500		186,305
Insurance		242,323		144,576		698,158		420,364		486,462		228,224		966,903		455,835
Investor relations		115,191		76,400		491,409		252,806		221,023		234,698		336,686		376,218
Office, insurance, IT and communications		141,919		50,792		271,293		181,340		117,785		74,719		297,533		129,374
Professional fees		246,480		182,006		925,174		597,778		259,603		342,213		525,742		678,694
Regulatory fees and transfer agent		16,947		23,202		95,410		114,920		71,864		40,619		139,152		78,463
Rent		7,703		10,197		42,274		41,838		2,015		18,500		6,907		34,571
Salaries and benefits		617,119		397,152		2,567,566		2,211,102		1,653,836		1,648,196		2,148,296		1,950,447
Share-based payments		1,540,150		1,126,007		4,329,428		4,782,351		741,494		1,871,717		1,982,234		2,789,278
Travel and other		6,337		5,501		12,443		93,715		2,658		1,742		36,578		6,106
Total	$	3,117,900	$	2,171,020	$	9,942,149	$	9,173,793	$	3,817,370	$	4,615,332	$	6,879,540	$	6,824,249

General and administration expenses increased to ~~$9,942,149~~$6,879,540 for the ~~nine~~six months ended ~~June 30, 2021~~March 31, 2022 from ~~$9,173,793~~$6,824,249 in the ~~nine~~six months ended ~~June 30, 2020~~March 31, 2021 and includes non-cash expense related to share-based payments of ~~$4,329,428 (2020~~$1,982,234 (2021 - ~~$4,782,351)~~$2,789,278). This non-cash expense relates to the value assigned to stock options and employees share purchase rights granted to key management and consultants of the Company. The expense is recognized in relation to the grant and vesting of these equity instruments, net of expiries and forfeitures, and allocated to research and development, general and administration and financing expenditures relative to the activity of the underlying optionee.

Director fees of ~~$271,055 (2020~~$169,500 (2021 - ~~$303,750)~~$186,305) were incurred for remuneration paid to directors ~~for attendance at meetings and~~as determined by committee participation ~~in various committees during the period.~~fee schedules.

Insurance expense of ~~$698,158 (2020~~$966,903 (2021 - ~~$420,364)~~$455,835) relates to increased cost of insurance coverage for directors and officers of the Company as a reporting issuer and publicly listed company in the United States, as well as general liability insurance. The Company has realized an increase in premiums which is in line with market trends.

~~Investor relations expense increased to $491,409 (2020 - $252,806) due to the cost of additional investor communications support engaged in the current period.~~

Professional fees of ~~$925,174 (2020~~$525,742 (2021 - ~~$597,778)~~$678,694) were incurred for legal and accounting services relative to variations in ~~conjunction with increased~~ corporate activities. ~~Over~~In the ~~periods presented,~~prior period, the Company ~~prepared for and~~ implemented changes with respect to its transition to a domestic issuer from foreign private issuer, including transition of financial statements to U.S. GAAP. The Company is now a US domestic issuer and has ongoing costs to support compliance and contracts.

~~Financing costs~~

In the nine months ended June 30, 2021, the Company incurred financing costs expense of $18,147 (2020 - $500,972). In the current period, the Company incurred a minimal amount finance accretion related to the operating lease. In the

4243

Table of Contents

~~comparative period, the Company settled a long-term debt with Silicon Valley Bank which resulted in a non-recurrent finance charge of $211,079.~~

Derivative liabilities

The Company has certain warrants treated as derivatives for financial reporting purposes. Consequently, the Company’s financial results are impacted by fluctuations in the market price of the Company’s common stock. These warrants are measured at fair value, with changes recognized in the statement of loss and comprehensive loss at each reporting date. During the ~~nine~~six months ended ~~June 30, 2021,~~March 31, 2022, the Company recorded the resulting change in fair value, largely resulting from the increase in stock price during the period and associated price volatility, of ~~$470,132 (2020~~$18,424 (2021 – ~~$60,242)~~gain of $1,039,086) in the statement of loss and comprehensive loss.

Three months ended ~~June 30,~~March 31, 2022 and 2021 ~~and 2020~~

The Company incurred a comprehensive loss of ~~$8,752,011~~$10,903,335 for the three months ended ~~June 30, 2021~~March 31, 2022 compared to a

comprehensive loss of ~~$4,924,828~~$12,965,247 for the three months ended ~~June 30, 2020.~~March 31, 2021. The detailed changes in R&D and G&A

expenses for the three months ended ~~June 30,~~March 31, 2022 and 2021 ~~and 2020~~ are included in the tables above.

For the three months ended ~~June 30, 2021,~~March 31, 2022, the Company’s R&D investment continued with the ongoing clinical trial

of EPI-7386. In the comparative period, the Company incurred R&D costs in relation to the Company’s clinical candidate EPI-7386 which was accepted by the FDA on April 30, 2020. This has resulted in increased clinicalClinical costs of ~~$1,156,860 (2020~~$1,112,940 (2021 - ~~$548,639), manufacturing costs of $1,409,283 (2020 - $650,760),~~$1,740,573) and ongoing preclinical costs and data analysis costs of ~~$1,268,068 (2020~~$2,357,100 (2021 - ~~$574,861). The Company continues to advance~~$961,487) support the clinical trial and associated analysis. Manufacturing costs of $1,838,612 (2021 - $2,654,734) reflect the ongoing production of drug and has ~~entered into collaboration agreements in the current quarter.~~decreased following initial production loads and narrowing of dosage parameters.

G&A expenses were ~~$3,117,900 (2020~~$3,817,370 (2021 - ~~$2,171,020)~~$4,615,332) for the three months ended ~~June 30, 2021.~~March 31, 2022. Professional fees of ~~$246,480 (2020~~

$259,603 (2021 - ~~$182,006)~~$342,213) have ~~increased and reflect compliance work~~decreased as ~~a US domestic issuer and significant contract work for~~there were collaboration contracts in the prior period. Salaries and benefits of ~~$617,119 (2020~~$1,653,836 (2021 - ~~$397,152)~~$1,648,196) for the three months ended ~~June 30, 2021 were~~March 31, 2022 include annual bonuses paid to senior management and employees during the period. Directors’ fees of $84,750 ~~(2020~~(2021 - ~~$101,250)~~$92,805) are paid to directors ~~relative to meeting attendance~~for their membership on the Board of Directors and for Board committee ~~participation.~~membership based on an annual fee structure. Insurance expense of ~~$242,323 (2020~~$486,462 (2021 - ~~$144,576)~~$228,224) has increased relative to the Company’s overall activity level and a market-wide increase toin insurance costs.

Share-based payments for research and development team members were ~~$1,243,792 (2020~~$1,121,859 (2021 - ~~$382,941)~~$791,969) and ~~$1,540,150 (2020~~$741,494

(2021 – ~~$1,126,007)~~$1,871,717) for key management and personnel allocated to general and administrative costs. Share-based

payments expense is non-cash and is estimated under the Black-Scholes method and expensed relative to vesting

conditions for the underlying stock options.

Liquidity and Capital Resources

ESSA is a clinical stage company and does not currently generate revenue.

As of ~~June 30, 2021,~~March 31, 2022, the Company has working capital of ~~$199,949,211~~$178,353,354 (September 30, ~~2020~~2021 - ~~$79,093,604)~~$193,668,414). Operational activities during the ~~nine~~three months ended ~~June 30, 2021~~March 31, 2022 were financed mainly by proceeds from the ~~acquisition of Realm,~~ financings completed in ~~August 2019,~~ July 2020 and February 2021. At ~~June 30, 2021,~~March 31, 2022, the Company had available cash reserves and short-term investments of ~~$202,263,003~~$181,018,439 (September 30, ~~2020~~2021 - ~~$78,332,100)~~$194,927,183) to settle current liabilities of ~~$3,008,727~~$3,748,803 (September 30, ~~2020~~2021 - ~~$1,203,324)~~$3,929,663). At ~~June 30, 2021,~~March 31, 2022, the Company believed that it had sufficient capital to satisfy its obligations as they became due and execute its planned expenditures for more than twelve months.

4344

Table of Contents

ESSA’s future cash requirements may vary materially from those now expected due to a number of factors, including the costs associated with future preclinical work and to take advantage of strategic opportunities, such as partnering collaborations or mergers and acquisitions activities. In the future, it may be necessary to raise additional funds. These funds may come from sources such as entering into strategic collaboration arrangements, the issuance of shares from treasury, or alternative sources of financing. However, there can be no assurance that ESSA will successfully raise funds to continue its operational activities. See ~~“Risk Factors”~~“Risk Factors” in our Annual Report on Form 10-K.

Critical Accounting Policies and Estimates

The Company makes estimates and assumptions about the future that affect the reported amounts of assets and liabilities. Estimates and judgments are continually evaluated based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. In the future, actual experience may differ from these estimates and assumptions.

The critical accounting policies are those polices that require the most significant judgments and estimates in the preparation of our condensed consolidated interim financial statements. A summary of the critical accounting policies is presented in Note 2 of the annual consolidated financial statements for the year ended September 30, ~~2020~~2021 filed with the SEC and with the securities commissions in Alberta and Ontario on ~~December 15, 2020.~~November 18, 2021.

Trend Information

ESSA is a clinical development stage company and does not currently generate revenue. The Company is focused on the development of small molecule drugs for the treatment of prostate cancer. The Company has acquired a license to certain Licensed IP. As of the date of this Quarterly Report on Form 10-Q, no products are in commercial production or use. The Company’s financial success will be dependent upon its ability to continue development of its compounds through preclinical and clinical stages to commercialization.

Off-Balance Sheet Arrangement

ESSA has no material undisclosed off-balance sheet arrangements that have, or are reasonably likely to have, a current or future effect on its results of operations, financial condition, revenues or expenses, liquidity, capital expenditures or capital resources that is material to investors.

Outstanding Share Data

As of ~~August 16, 2021,~~May 10, 2022, our authorized share capital consisted of an unlimited number of common shares, each without par value, of which ~~43,984,346~~44,059,700 were issued and outstanding, and an unlimited number of preferred shares, each without par value, none of which were issued and outstanding. As of ~~August 16, 2021,~~May 10, 2022, we had 3,234,750 common shares issuable pursuant to 3,234,750 common share purchase warrants pursuant to full cash exercise, ~~2,694,698~~4,106,409 common shares issuable pursuant to ~~2,694,698~~4,106,409 exercisable outstanding stock options, ~~4,108,532~~2,664,069 common shares issuable pursuant to ~~4,108,532~~2,664,069 outstanding options that were not exercisable at that date, and no outstanding restricted stock units.

~~Table of Contents~~

~~JOBS Act~~

As a company with less than US$1.07 billion in revenue during the last fiscal year, ESSA qualifies as an “emerging growth company” pursuant to the JOBS Act. An emerging growth company may take advantage of specified exemptions from various requirements that are otherwise applicable generally to public companies in the United States.

The JOBS Act also permits an emerging growth company such as ESSA to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies. ESSA will not take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. This election is irrevocable. ESSA will remain an emerging growth company until the earliest of:

●

~~the last day of the Company’s fiscal year during which it has total annual gross revenues of at least US$1.07 billion;~~

●

~~the last day of the Company’s fiscal year following the fifth anniversary of the completion of an initial public offering;~~

●

~~the date on which Company has, during the previous three-year period, issued more than US$1 billion in non-convertible debt securities; or~~

●

the date on which the Company is deemed to be a “large accelerated filer” under the Exchange Act, which would occur if the market value of ESSA’s common shares that are held by non-affiliates exceeds US$700 million as of the last business day of its most recently completed second fiscal quarter.

As a result of ESSA’s status as an emerging growth company, the information that the Company provides shareholders may be less comprehensive than what you might receive from other public companies that are not emerging growth companies. When ESSA is no longer deemed to be an emerging growth company, ESSA will not be entitled to the exemptions provided in the JOBS Act.

Safe Harbor

See “Cautionary Note Regarding Forward-Looking Statements” in the introduction to this Quarterly Report.

Table of Contents

Item 3. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

As of end of the period covered by this Quarterly Report on Form 10Q, our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the design and operating effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act of 1934. Our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports that the Company files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Any such information is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate, to allow timely decisions regarding required disclosure.

Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on our evaluation of our disclosure controls and procedures as of the end of the period covered by this report, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were, in design and operation, effective at the reasonable assurance level.

Management’s Annual Report on Internal Control over Financial Reporting

Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, is responsible for establishing and maintaining adequate internal control over our financial reporting, defined in Rule 13a-15(f) and Rule 15d-15(f) of the Exchange Act.

The effectiveness of any system of internal control over financial reporting, including ours, is subject to inherent limitations, including the exercise of judgment in designing, implementing, operating, and evaluating the controls and procedures, and the inability to eliminate misconduct completely. Accordingly, any system of internal control over financial reporting, including ours, no matter how well designed and operated, can only provide reasonable, not absolute, assurances. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions or that the degree of compliance with the policies or procedures may deteriorate. Management has assessed the effectiveness of our internal control over financial reporting as of ~~June 30, 2021.~~March 31, 2022. In making its assessment, management used the criteria set forth in the internal control – integrated framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 COSO framework) to evaluate the effectiveness of our internal control over financial reporting. Based on this evaluation, management has concluded that our internal control over financial reporting was effective as of ~~June 30, 2021.~~March 31, 2022.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting during the quarter ended ~~June 30, 2021~~March 31, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

From time to time, we may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business. As of ~~June 30, 2021,~~March 31, 2022, we are not a party to any legal proceedings that, in the opinion of our management, would reasonably be expected to have a material adverse effect on our business, financial condition, operating results or cash flows if determined adversely to us. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.

Item 1A. Risk Factors

There have been no material changes in our risk factors from those disclosed in our Annual Report on Form 10-K for the year ended September 30, ~~2020.~~

2021.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

Table of Contents

Item 6. Exhibits

Exhibit No.


3.1	Articles of Incorporation (incorporated by reference to Exhibit 1 to the Company’s Registration Statement on Form 20-F (File No. 377-00939), originally filed with the SEC on February 24, 2015)
4.1	Specimen common share certificate (incorporated by reference to Exhibit 4.1 to the Registrant’s Registration Statement on Form S-8, filed with the Commission on May 18, 2018 (File No. 333-225056))
31.1	Certification of the Chief Executive Officer pursuant to Rule 13a-14(a) of the Securities and Exchange Act of 1934, as amended
31.2	Certification of the Chief Financial Officer pursuant to Rule 13a-14(a) of the Securities and Exchange Act of 1934, as amended
32.1	Certification by the Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350 as added by Section 906 of the Sarbanes-Oxley Act of 2002
101.INS	Inline XBRL Instance Document – The instance document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document. *
101.SCH	Inline XBRL Taxonomy Extension Schema Document *
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document *
101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document *
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document *
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document *
104	Cover page from the Company’s Annual Report on Form 10-K for the year ended September 30, ~~2020~~2021 formatted in Inline XBRL (included in Exhibit 101).

†Confidential treatment has been requested for portions of this document. The omitted portions of this document have been filed with the Securities and Exchange Commission.

* Filed herewith.

Table of Contents

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: ~~August 16, 2021~~May 10, 2022


	ESSA PHARMA INC.
	(Registrant)

	By:	/S/ DAVID PARKINSON
	Name:	David Parkinson
	Title:	Chief Executive Officer

	By:	/S/ DAVID WOOD
	Name:	David Wood
	Title:	Chief Financial Officer



	For the three months ended				For the nine months ended
	June 30,				June 30,
	2021		2020		2021		2020

OPERATING EXPENSES
Research and development	$	6,231,908	$	2,703,704	$	17,985,937	$	9,909,288
Financing costs (Notes 7 and 8)		16,667		197,102		18,147		500,972
General and administration		3,117,900		2,171,020		9,942,149		9,173,793

Total operating expenses		(9,366,475)		(5,071,826)		(27,946,233)		(19,584,053)

Foreign exchange		(34,084)		10,937		(19,239)		(685)
Interest income		80,394		172,346		155,293		478,952
Derivative liability gain (loss) (Note 9)		568,954		(36,285)		(470,132)		(60,242)

Loss for the period before taxes		(8,751,211)		(4,924,828)		(28,280,311)		(19,166,028)

Income tax recovery (expense)		(800)		0		34,349		274,000

Loss and comprehensive loss for the period	$	(8,752,011)	$	(4,924,828)	$	(28,245,962)	$	(18,892,028)

Basic and diluted loss per common share	$	(0.21)	$	(0.24)	$	(0.76)	$	(0.91)

Weighted average number of common shares outstanding – basic and diluted		41,018,024		20,824,568		36,937,014		20,802,026


Operating lease right-of-use asset
Balance, September 30, 2019	$	0
Adoption of ASC 842		165,486
Amortization		(82,743)

Balance, June 30, 2020	$	82,743

Balance, September 30, 2020	$	55,162
Addition		323,036
Amortization		(80,665)

Balance, June 30, 2021	$	297,533


Operating lease liabilities
Balance, September 30, 2019	$	0
Adoption of ASC 842		165,486
Accretion		10,893
Lease payments		(89,096)

Balance, June 30, 2020	$	87,283

Balance, September 30, 2020	$	59,094
Addition		323,036
Accretion		5,497
Lease payments		(69,637)

Balance, June 30, 2021	$	317,990